

EXHIBIT D



US008859562B2

(12) **United States Patent**
Helleday

(10) **Patent No.:** US 8,859,562 B2
(45) **Date of Patent:** Oct. 14, 2014

- (54) **USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER**
- (75) Inventor: **Thomas Helleday**, Stockholm (SE)
- (73) Assignee: **The University of Sheffield**, Sheffield (GB)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 2568 days.

- (21) Appl. No.: **10/555,507**
- (22) PCT Filed: **Jul. 23, 2004**
- (86) PCT No.: **PCT/GB2004/003235**
 § 371 (c)(1),
 (2), (4) Date: **Sep. 15, 2006**
- (87) PCT Pub. No.: **WO2005/012524**
 PCT Pub. Date: **Feb. 10, 2005**
- (65) **Prior Publication Data**
 US 2007/0179160 A1 Aug. 2, 2007

(30) **Foreign Application Priority Data**

Jul. 25, 2003 (GB) 0317466.1

- (51) **Int. Cl.**
A61K 31/495 (2006.01)
A61K 31/33 (2006.01)
A61K 31/435 (2006.01)
A61K 38/00 (2006.01)
C07D 487/06 (2006.01)
C12N 15/113 (2010.01)
A61K 31/5517 (2006.01)
- (52) **U.S. Cl.**
 CPC *C07D 487/06* (2013.01); *A61K 38/005* (2013.01); *C12N 15/1137* (2013.01); *A61K 31/5517* (2013.01); *C12Y 204/0203* (2013.01); *C12N 2310/14* (2013.01)
 USPC **514/258.1; 514/299; 514/388**

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,098,861 A	3/1992	Blackstone
5,484,951 A	1/1996	Kun et al.
5,519,053 A	5/1996	Kun et al.
5,652,367 A	7/1997	Kun et al.
6,548,494 B1 *	4/2003	Webber et al. 514/220
7,072,771 B2 *	7/2006	Oliveira 702/27
7,087,637 B2	8/2006	Grandel et al.
7,176,188 B2	2/2007	Desnoyers
2003/0229004 A1	12/2003	Zarling et al.
2005/0227919 A1	10/2005	Ashworth et al.
2006/0142231 A1	6/2006	Ashworth et al.

FOREIGN PATENT DOCUMENTS

EP	0600831	A1	11/1993
WO	WO 95/24379		9/1995
WO	WO 9908680	A1 *	2/1999
WO	00/42040		7/2000
WO	01/16136		3/2001
WO	WO 02/12239		2/2002
WO	WO 02/36576	A1	5/2002
WO	WO 02/090334	A1	11/2002
WO	WO 03/014090	A1	2/2003
WO	WO 03/063874	A1	8/2003
WO	WO 03/070234	A1	8/2003
WO	WO 03/093261	A1	11/2003
WO	WO 2004/008976	A1	1/2004

OTHER PUBLICATIONS

- Gan et al., Specific interference with gene expression and gene function mediated by long dsRNA in neural cells, Journal of Neuroscience Methods, 121, 2002, pp. 151-157.*
 Cecil Textbook of Medicine, 1997, 20th Edition, vol. 1, pp. 1007-1010.*
 Sausville et al. (Cancer Research, 2006, vol. 66, pp. 3351-3354).*
 Johnson et al. (British J. of Cancer, 2001, 84(10):1424-1431).*
 Thacker, J., Cancer Letters, 2005, vol. 219, pp. 125-135.*
 BG483078, <http://mgc.nci.nih.gov/>, National Institutes of Health, Mammalian Gene Collection (MGC, Unpublished, 1999, Contact: Robert Strausberg, Ph.D, Tissue Procurement: CLONTECH Laboratories, Inc.
 Elbashir et al., Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells, Nature, 2001, 411: 494-498.
 Larminat et al., Deficiency in BRCA2 Leads to Increase in Nonconservative Homologous Recombination, Oncogene, 2002, 21: 5188-5192.
 Massuda et al., PARP Inhibitor, Down-Regulates Metastasis Associated S100A4 (MTS1) and Suppresses Invasion of Breast Cancer Cells In Vitro, Proceedings of the American Association for Cancer Research, 2003, 44 (2nd ed), 867-868.
 Schultz et al., Poly (ADP-Ribose) Polymerase (PARP-1) Has a Controlling Role in Homologous Recombination, Nucleic Acids Research, 2003, 31(17): 4959-4964.
 Shall et al., Poly(DP-Ribose) Polymerase-1: What Have We Learned From the Deficient Mouse Model?, Mutation Research, 2000, 460: 1-15.
 Weltin et al., Effect of 6(5H)-Phenanthridinone, An Inhibitor of Poly(ADP-Ribose) Polymerase, on Cultured Tumor Cells, Oncology Research, 6(9): 399-403.

(Continued)

Primary Examiner — James D Anderson

(74) *Attorney, Agent, or Firm* — Bozicevic, Field & Francis LLP; Pamela J. Sherwood

(57) **ABSTRACT**

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

US 8,859,562 B2

Page 2

(56)

References Cited**OTHER PUBLICATIONS**

- Gallmeier et al., Absence of Specific Cell Killing of the BRCA2-Deficient Human Cancer Cell Line CAPAN1 by Poly(ADP-Ribose) Polymerase Inhibition, 2005 *Cancer Biol. & Ther.*, 4(7): 703-706.
- McCabe et al., BRCA2-Deficient CAPAN-1 Cells Are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase, 2005, *Cancer Biol. & Ther.*, 4(9): 934-936.
- Jönsson, Göran; et al., "High-Resolution Genomic Profiles of Breast Cancer Cell Lines Assessed by Tiling BAC Array Comparative Genomic Hybridization", *Genes, Chromosomes and Cancer*, 2007, 46:543-558.
- Sanger Institute database entry for MDA_MB-231, Catalogue of Somatic Mutations in Cancer, 2 pgs.
- Turner, Nicholas; et al., "Hallmarks of 'BRCAAness' in sporadic cancers", *Nature Reviews*, Oct. 2004, 4:1-6.
- Wooster, Richard; et al., "Breast and Ovarian Cancer", *The New England Journal of Medicine*, Jun. 5, 2003, 348:2339-47.
- Bernstein, C., et al., "DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis," (2002) *Mutation Research*, 511:147-178.
- Bryant, H., et al., "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase," (2005) *Nature*, 434:913-917.
- Farmer, H., et al., "Targeting the DNA repair defect in *BRCA* mutant cells as a therapeutic strategy," (2005) *Nature*, 434:917-921.
- Watchers, F., et al., "Selective targeting of homologous DNA recombination repair by gemcitabine," (2003) *Int. J. Radiation Oncology Biol. Phys.*, 57(2):553-562.
- Banasik, Marek; et al., "Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferase", *The Journal of Biological Chemistry*, Jan. 25, 1992, 267(3):1569-1575.
- Calabrese, Christopher R; et al., "Identification of Potent Nontoxic Poly (ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies", *Clinical Cancer Research*, Jul. 2003, 9:2711-2718.
- Cepeda, Victoria; et al., "Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy", *Recent Patents on Anti-Cancer Drug Discovery*, 2006, 1:39-53.
- Dillon, Krystyna J; et al., "A FlashPlate Assay for the Identification of PARP-1 Inhibitors", *J. Biomol Screen*, 2003, 8(3):347-352.
- Ferraris, Dana; et al., "Design and Synthesis of Poly ADP-ribose Polymerase-1 Inhibitors. 2. Biological Evaluation of Aza-5[H]-phenanthridin-6-ones as Potent, Aqueous-Soluble Compounds for the Treatment of Ischemic Injuries", *J. Med. Chem.*, 2003, 46:3138-3151.
- Griffin, RJ; et al., "The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy", *Biochimie*, 1995, 77:408-422.
- McCabe, Nuala; et al., "Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly (ADP-Ribose) Polymerase Inhibition", *Cancer Res*, Aug. 15, 2006, 66(16):8109-8115.
- Virág, Laszlo; et al., "The Therapeutic Potential of Poly (ADP-Ribose) Polymerase Inhibitors", *Pharmacological Reviews*, 2002; 54(3):375-429.
- Dudas, Andrej; et al., "DNA double-strand break repair by homologous recombination", *Mutation Research*, 2004, 566:131-167.
- Hoeijmakers, Jan H. J.; et al., "Genome maintenance mechanisms for preventing cancer", *Nature*, May 17, 2001, 411:366-374.
- Khanna, Kum Kum; et al., "DNA double-strand breaks: signaling, repair and the cancer connection", *Nature Genetics*, Mar. 2001, 27:247-254.
- Fong; et al., "AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study", *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 5510).
- Hao; et al., "BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR", *Int. J. Cancer* (2007), 121:39-46.
- Lau; et al., "Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer", *EORTC* 2008 Geneva, poster #557.
- Calabrese; et al., "Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies", *Clinical Cancer Research* (2003), 9:2711-2718.
- Berthet; et al., "DNA repair inhibitors", *Expert Opinion on Therapeutic Patents* (1999), 9(4):401-415.
- Perkins, et al., "Novel Inhibitors of Poly(ADP-ribose) Polymerase/ PARP1 and PARP2 Identified Using a Cell-based Screen in Yeast", *Cancer Research* (2001), 61:4175-4183.


* cited by examiner

U.S. Patent

Oct. 14, 2014

Sheet 1 of 20

US 8,859,562 B2

Figure 1.


U.S. Patent

Oct. 14, 2014

Sheet 2 of 20

US 8,859,562 B2

Figure 2.




U.S. Patent

Oct. 14, 2014

Sheet 3 of 20

US 8,859,562 B2

Figure 3




U.S. Patent

Oct. 14, 2014

Sheet 4 of 20

US 8,859,562 B2

Figure 4




U.S. Patent

Oct. 14, 2014

Sheet 5 of 20

US 8,859,562 B2

Figure 5A






U.S. Patent

Oct. 14, 2014

Sheet 6 of 20

US 8,859,562 B2



U.S. Patent

Oct. 14, 2014

Sheet 7 of 20

US 8,859,562 B2





FIG. 6

U.S. Patent

Oct. 14, 2014

Sheet 8 of 20

US 8,859,562 B2




U.S. Patent

Oct. 14, 2014

Sheet 9 of 20

US 8,859,562 B2



U.S. Patent

Oct. 14, 2014

Sheet 10 of 20

US 8,859,562 B2

FIGURE 9

U.S. Patent

Oct. 14, 2014

Sheet 11 of 20

US 8,859,562 B2

2821 ggtgggttag aagcagaaaag taaatattat ccagtccgc acaggttaca aggagctatt
 2881 ttctatcc aagcatatca caagcaatac cgccgcagca gagttcatca tgctgcccac
 2941 acctaccatg gggAACACAG acttctggaa aacactccga tatcttagct tattgtaccc
 3001 tgctcgaggg tcacggaaca tcctccttgt gtctgatggg caccctcagg atgagagcct
 3061 gacattacag ctctgtgaga ggagccccc gcacaccagg ttatcgctt gcggtatcg
 3121 ttctacagca aatctgtcac tcttaaggat ttgtccccag tgggtgcgg gagtatttg
 3181 alaltttaat gaaaaatcca agcatagttg gagaaaacag atagaagacc aaatgaccag
 3241 gctatgttc cggagggtgc actctgtctc cgtcaaatttgg cagcaactca atccagatgc
 3301 gccccgggcc ctgcaggccc cagcccagggt gccatccttgc ttgcataatg atcgactcct
 3361 tgctatggta ttcatccctc actgcacaca ggcaactctg tggactaa ttcaagagaa
 3421 agaattttgt acaatgggtg cgtactactga gcttcaggaa acaactggaa ctatgttcca
 3481 caagctggea gccccgggtc taatcagaga ttatgaaatgg ggcatttc acgaaaatga
 3541 aaccaggcat gagatgaaaa aacaaacctt gaaatctctg attattaaac tcaagaaaga
 3601 aaactcttc ataacacaat ttacaagctt tggtcgatgg gaaaaaggg atgagaatga
 3661 gtcacccctt ctgtatatic caaaaatgttca tgaacttattt gccaaaggaaatgg atgttagactt
 3721 ctcggccctac atgagctggc agggggaaacc ccaagaagcc gtcaggaacc agtctttt
 3781 agcatcttcctc ggtggccag aattacgtttt atccaaacga aaacatagga aaattccatt
 3841 ttccaaaaga aaaatggaat tatctcagcc agaattttctt gaagattttg aagaggatgc
 3901 cttaggtgtttaaccatccatcaaa ttggaaacgt ggacgtgtgg aaaaagctt
 3961 ggatttaagt tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaagt
 4021 cagtccatgg gaaacatcta ctcttagttt tttccattttt tggctccgg ccgttgttcc
 4081 ctatcttacc cggacttaccc ggggtcacag tccgtcttcc ttgtctttt ctcatatcg
 4141 tcaggtagct agtttcgggtt cagctgtcc tcccagacag ttgtatgtatccatcttc
 4201 ccaaggccctt gtgcctggca ctgtgtgttca ctggatccca cagtcggcgt ctgtccac
 4261 aggacccccc cagaaccacac ctctgttccatccatccatccatccatccatccatccatcc
 4321 attaagctctc gcacagtctc ctccactgtca acatcttggaa ggcttacta ccaggccctc
 4381 tgctggcacc ttcccttgc tggattctcc ccagtttcat ttcctcttc ctacagaccc
 4441 tgatccccatc agaggatggt ggtttatca tccctctgt tactctctttt ttcattttca
 4501 accttccgcac cccttccatccatccatccatccatccatccatccatccatccatccatccatcc
 4561 ggcttccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
 4621 aggacgttc gaaggaatgtc gatgttccatccatccatccatccatccatccatccatccatcc
 4681 tgatgagcttca tcaagacag ctgttttttcaaaatggataaaaatggataaaaatggataaaa
 4741 agatgacagt atccctgttca ttcatttttca ttcatttttca ttcatttttca ttcatttttca
 4801 acactggcag gatgttccatccatccatccatccatccatccatccatccatccatccatccatcc
 4861 ctggaaacit acaccagaac tggacttatttattaaatctt aataaaaaatggataaaaatggataaaa
 4921 ctgttttttcaaaaatggca ttcaatcttca ttcatttttca ttcatttttca ttcatttttca
 4981 ctcatttttca acaatgttccatccatccatccatccatccatccatccatccatccatccatcc
 5041 agtttccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
 5101 ttgttccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
 5161 tatctgttccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
 5221 actccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
 5281 agtcaatgttca aactgttccatccatccatccatccatccatccatccatccatccatccatcc
 5341 ataatagata ttataatgttca aactgttccatccatccatccatccatccatccatccatccatcc
 5401 taaaaatgttca aactgttccatccatccatccatccatccatccatccatccatccatccatccatcc
 5461 cttaaaaatgttca

Figure 9 (continued)

U.S. Patent

Oct. 14, 2014

Sheet 12 of 20

US 8,859,562 B2

Figure 10

1 ctagaattca gcggccgcgtg aattcttaggc ggcgccggcgg cgacggagca cccggcggcgg
61 cagggcgaga gcattaaatg aaagcaaaag agttaataat ggcaacacgg ctccagaaga
121 ctcttcctt gccaagaaaa ctcgttagatg ccagagacag gagtcgaaaa agatgcctgt
181 ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag
241 gtcatgggcc agcaaaggaa tctctgaatc tgtgaaggcc ttgctgttaa agggcaaagc
301 tcctgtggac ccagagtgtc cagccaagggt ggggaaggct catgtgtatt gtgaaggaaa
361 tgatgttat gatgtcatgc taaatcagac caatctccag ttcacaaca acaagtacta
421 tctgattcag ctattagaag atgatgccc gaggaacttc agtgttggta tgagatgggg
481 cccgagttggg aaaatgggac agcacagcct ggtggcttgt tcaggcaatc tcaacaaggc
541 caaggaaatc ttccagaaga aatttccttgcaaaaacgaaa aacaatggg aagatcgaga
601 aaagtttgag aagggtgcctg gaaaatatga tatgtcatac atggactatg ccaccaatac
661 tcaggatgaa gaggaaacaa aaaaagagga atctttaaa tctcccttgca agccagatgc
721 acagctagat ctccgggtac aggagttat aaagtgtatc tgtaatgttc aggccatgga
781 agaaatgtatg atgaaatgtc agtataatac caagaaagcc ccacttggga agctgacatgt
841 ggcacaaatc aaggcagggtt accagtctt taagaagattt gaggattgtt ttcgggttgg
901 ccagcatgga cgagcttc tggaaagcatg caatgaattc tacaccaggaa ttccgcattgaa
961 ctttggactc cgtactccctc cactaatccg gacacagaag gaactgtcag aaaaaataca
1021 attactagag gctttgggag acatttataat tgcttataag ctggtaaaaaa cagactaca
1081 aagcccagaa cacccattgg accaacacta tagaaaccta catttgccct tgcccccct
1141 tgaccatgaa agttacgatg tcaaagtgtt ttcccatgtc ctacaatctt cccatgtcc
1201 cacacacgc gactatacca tgacccttgc ggattttttt gaagttggaga aggatggta
1261 gaaagaagcc ttccagaggagg accttcataa caggatgtt ctatggcatg gtccaggat
1321 gagtaactgg gtggaaatct tgaccatgg gcttcgaaattt gcccacccctg aagctcccat
1381 cacagggttac atgtttgggaa aaggaatcta ctttgctgac atgtcttcca agatgtccaa
1441 ttaactgtt cccttcgc taaagaatatac aggactgttgc ctcttatac aggtatgtt
1501 aggtcagttt atatgtatc tagaggccaa tccttaaggcc gaaggatgtc ttcaaggtaa
1561 acatagcacc aaggggctgg gcaagatggc tcccaggatctt gcccacttgc tcaccctgaa
1621 tgggagttaca gtggcattttt gaccagaag tgacacagga attctgtatc cagatggta
1681 taccctcaac tacaatgtatc atattgtata taaccccaac cagggtccgtt tgccgttac
1741 tttaaagggtt cagttttttt tcccttcagttt gtggtaatgtt ttatgtttttaaataaaccaga
1801 gatctgtatct tcaagcaaga aaataaaggcag tttttttttt gtgtttttt gtgttttttta
1861 tgtaataaaaaa actgtacagg tctaaaaaaa aaaaaaaaaa aaaaaaaaaaaa

//

U.S. Patent

Oct. 14, 2014

Sheet 13 of 20

US 8,859,562 B2

Figure 11

1 tggactggc cgccgtactc ggcctgcccc agcctctgct tcaccccact ggtggccaaa
61 tagccatgt ctaatcccc acacaagctc atccccggcc tctggattt tgccaattc
121 tctccataat tcacgcctga ggctcatgga gagttgctag acctggact gccctggag
181 ggcacaccaa ccaggccggg tggcagccag gaccctctcc atgtccctgc ttitctggc
241 catggctcca aagccgaagc cctgggtaca gactgaggc cctgagaaga agaaggggccg
301 gcaggcagga agggaggagg acccccttcg ctccaccgct gaggccctca aggccatacc
361 cgcagagaag cgcataatcc gcgtggatcc aacatgttca ctcagcagca accccgggac
421 ccaggtgtat gaggactaca actgcaccc gaaccagacc aacatcgaga acaacaacaa
481 caagtctac atcatccagc tgctccaaga cagcaaccgc ttctcacct gctgaaaccg
541 ctggggccgt gtgggagagg tcggccagtc aaagatcaac cacttcacaa ggctagaaga
601 tgcaaagaag gacttgaga agaaatttcg gggaaagacc aagaacaact gggcagagcg
661 ggaccactt gtgtctcacc cggcaagta cacacttatac gaagtacagg cagaggatga
721 gcccagga gctgtggta aggtggacag aggcccagtg aggactgtga ctaagcgggt
781 gcagccctgc tccctggacc cagccacgca gaagctcatc actaacatct tcagcaagga
841 gaigtcaag aacaccatgg ccctcatgga cctggatgtg aagaagatgc ccctgggaaa
901 gctgagcaag caacagattt caggggtt cggcccttg gaggcgtgg aggaggccct
961 gaaaggcccc acggatggg gccaaaggct ggaggagctg tcctcacact ttacaccgt
1021 catcccgcac aacttcggcc acagccagcc cccggccatc aatccccctg agctctgca
1081 ggccaagaag gacatgctgc tggctggc ggacatcgag ctggcccagg ccctgcaggc
1141 agtctctgag caggagaaga cggtgagga ggtgccacac ccctggacc gagactacca
1201 gcttctcaag tgccagctgc agctgttca ctcggagca cctgagtaca aggtgatata
1261 gacctactta gaacagactg gcagcaacca caggtccctt acactcaac acatctggaa
1321 agtaaaccaa gaagggggagg aagacagattt ccagcccac tccaaactgg gtaatcgaa
1381 gctgctgtgg catggcacca acatggcgt ggtggccggc atccacta gtggctccg
1441 catcatgcca cattctggtg ggcgttgttgg caagggcatc tactttccct cagagaacag
1501 caagtcagct ggtatgttta ttggcatgaa gtgtggggcc caccatgtcg gctacatgtt
1561 cctgggttagt gtggccctgg gcagagagca ccatatcaac acggacaacc ccagcttggaa
1621 gagcccaccc tctggcttcg acagtgtcat tgccggaggc cacaccgagc ctgtatccgac
1681 ccaggacact gagttggagc tggatggca gcaagtgggtg gtggcccagg gccagccctgt
1741 gcccgtccca gagttcagca gctccacattt ctccttggc ggtttttttt tttttttttt
1801 gagccagttt cgcctgcgtt acctgttggt ggtccaccc tcgttggccgg ccctgtcccc
1861 cggggctctg caaggcttggta ctgttgcattt caatcatctt gcccacatctt ggttacccctt
1921 tatcaacttctt tttttcaag aatacaatac gtttttttttta actatagtca ccatgtgtt
1981 caagatccctt gaaacttgc ctccttactt aaattttttttta ttttttttttta catctggccca
2041 gtccctctcc tcccttggccca tggtaaccag catttgactt ttacttttttta taagggcagc
2101 ttttttttttta ttttttttttta ttttttttttta ttttttttttta ttttttttttta ttttttttttta
2161 ttttttttttta ttttttttttta ttttttttttta ttttttttttta ttttttttttta ttttttttttta
2221 ctttttttttta aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaa

U.S. Patent

Oct. 14, 2014

Sheet 14 of 20

US 8,859,562 B2

Figure 12

```

1 cgaagatggc ggcgtcgctg cgctctcaga atcatcacca ccatcatcaa caacagctcc
61 agcccccccc aggggcttca gcgcgcgcgc cgcacactcc tccccactc agccctggcc
121 tggccccggg gaccacccca gctctccca cggccagcgg cctggccccc ttgcctccc
181 cggccacgg cttagcgctg cggaggggg atggdagtgc ggatccgccc gacaggcccc
241 gatccccggg cccgggttgc ggtaccagct gttcagtc caccagcaca atctgtaccc
301 tcgcgcgcgc tcccggttgc ccagcggtt ctacttcata tgccgttggg gtgcctcca
361 accccagcggg cagtgccatg aacaattcac cgtcgctc tttttccccg acttcttcot
421 catttcttc tccatcctcc cctggatcga gcttggcggg gagccccggag gggccggag
481 ttagcagcac agcaccactg gggcctgggg cagcaggacc tgggacaggg gtcccgacag
541 tgagcggggc cctacggaa ctgtggggg cctgtcgcaaa tggggacgtg tcccggttaa
601 agaggctgtt ggacgcggca aacgttaatg caaaggacat ggcggccggg aagtcttctc
661 ccctgactt cgtcgatggg tttggaaagg agatgttgtt agaaacacttta ctacagatgg
721 gtgcataatgt ccacgtcgat gatgtatgg qtcataatcc gtttcataat gctgttctt
781 ttggccatgc tgaggttgc agtctgtt tttgtccaaagg agtgcataa aatgccagg
841 ataactggaa ctatacacct ctgcataaag ctgttattaa agggaaagatc gatgtgtgca
901 ttgtgtgtgtt gcaagcggaa gctgacccaa acatccggaa cactgtatggg aaatcagccc
961 tggacccctggc agatcccttc gcaaaaatgtg tccctacagg tgaatacaag aaagacgaa
1021 tocttagaagg tgcgttggat ggtatggaa aaaaaataat ggtttactg actcctctaa
1081 atgtgaattt gcatgcataa gatggggaa agtgcactcc tttacatcta gcaagcgggt
1141 acaacagatc tgcataatgtt cagcttcttc ttcagcatgg tgctgtatgtt catgaaaag
1201 acaaagggtgg acttgcgtt cttcataatg catgttcata tggacattat gaagtcaac
1261 aactgtactt aaagcatgg aacttgcgtt atgcacatgg ttcctggcag tttactccac
1321 tgcacgggg tgcttccaaag aaccgtgttag aacttgcgtt tttgttactt agccatgggg
1381 ctgatccctac gttgtcaac tgccatggca aaaaatgtgtt ggtatggct ccaactccgg
1441 agcttagggaa gagattgtat tatgaattt aagggttccatc tttactacaa gcaagccag
1501 aaggcagactt agctaaatgg aaaaaaacac tegtctggaa aatcattat ttcacaaac
1561 cgcagtttc tgcacatgg tgcacatgg ttcgttccatc aaacgtaaac
1621 aagtgcacata attgttactt aaaaaaggag caaatgtttaa tggaaaaat aaagatrrca
1681 tgactccccc gcatgttgc gccggaaagg cccataatgt tgcatggaa gttctgcata
1741 agatggcgc caagatgtt gcaacttgc acactggaca ccctgggttca gactgttttgcatagagcc
1801 cccttagcagg ccacccctggc acctggccgc tccctgttgc ttacggctt gacccctcca
1861 tcatctccctt acaaggcttc acagcagcac agatggcggaa tgaaggcgtg cagcagattc
1921 tgatgtgttag ttacggctt gaccccttca tcatctccctt acaaggcttc acagcagcac
1981 agatggccaa tgaagcgtg cagcagatcc tgatgtgtca ttctgttgcata gttctgcata
2041 tacttgcgtt ttaatgttgc tttgttgc ggaagatgg aaggaaaatc tatccagcat
2101 gtcttcactt tcaacatggaa gagatcacctt atacttgcgtt tttacttgcata
2161 ttagaggcat taaaatgttgg agacttggaa actgttgcgtt aacttttgcgtt ctctcaaat
2221 gtgaatttgcataa gagacttgcataa gggccggcat tccacggccct tacacttgc acaggctac
2281 aacagagatc acctataatgtt acttgcgtt tttgttgcata acttgcgtt gcatctaaag
2341 ctggagactt ggaaacttgc aagcaactt gcaatgttgcata aatgttgcata tttacttgcata
2401 tagaggccgc gcatgttgc accttgcatac tttgttgcata gcaacccgc gttctgttgc
2461 tagatgttgcatac gtttgcgttgc tttgttgcataa agaaaatgttgcata gttctgttgc
2521 cccttcataa tgcctgttca tttgttgcata tttgttgcata gttctgttgcata gttctgttgc
2581 gggcttctgtt caatgttgcata gtttgcata tttgttgcata gttctgttgcata gttctgttgc
2641 aaggaaaatgttgcataa tttgttgcata tttgttgcata gttctgttgcata gttctgttgc
2701 acagagatgg aaatcacctt ttgttgcata tttgttgcata gttctgttgcata gttctgttgc
2761 tactgttgcata gtttgcata tttgttgcata gttctgttgcata gttctgttgcata gttctgttgc
2821 aagatgttgcata tttgttgcata gtttgcata gttctgttgcata gttctgttgcata gttctgttgc
2881 ctctgcaccc ggcaggccgc tttgttgcata gtttgcata gttctgttgcata gttctgttgcata
2941 gagatgttgcata tttgttgcata gtttgcata gttctgttgcata gttctgttgcata gttctgttgc
3001 atggccatgt tttgttgcata gtttgcata gtttgcata gttctgttgcata gttctgttgcata
3061 ataaggccgc gtttacttcc tttgttgcata gtttgcata gtttgcata gttctgttgcata
3121 cccttccttcc tttgttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3181 tttgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3241 ctttgcata tttgttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3301 catccacccca tttgttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3361 cagatgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3421 aggttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3481 ttgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3541 tttgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3601 tttgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3661 atctgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3721 cttgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3781 gtttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata
3841 agcgttgcata gtttgcata gtttgcata gtttgcata gtttgcata gttctgttgcata

```

U.S. Patent**Oct. 14, 2014****Sheet 15 of 20****US 8,859,562 B2**

3901 gcatgttgtt tcatggttct ccttcattta atgccattat tcataaaaggg ttgtatgagc
3961 gacatgcata cataggagga atgttgggg ccgggattta ttttgcgtcaa aactccctcaa
4021 aaagcaacca atatgttat ggaattggag gggaaacagg ctgcctaca cacaaggaca
4081 ggtcatgcta tatatgtcac agacaaaatgc tcattctgttag agtgaccctt gggaaatcct
4141 ttctgcagt tagcaccatg aaaatggccc acgcgcctcc agggcaccac tcagtcatcg
4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg
4261 catacccaga gtatcttac acttaccaga tcatgaagcc agaagccct tcccagaccc
4321 caacagccgc agagcagaag accttagtcaa tgccctgtgg tgaaggccag atcagatttc
4381 aacctgggac tggattacag aggattgttt ctaataacaa catcaatattt ctagaagtcc
4441 ctgacagcct agaaataagc tggttgtctt ctataaaagca ttgctatagt g

Figure 12 (continued)

U.S. Patent

Oct. 14, 2014

Sheet 16 of 20

US 8,859,562 B2

Figure 13

1 cgccgcgcct cgctagccga aacctgcca gcccgtgcc ggccactgcg cacgcgcggg
 61 acgcacgtcac gtgcgcgtccc ggggcgtggac ggagctggca ggaggggcct tgcgcacgtt
 121 cgcgcgcgc tcgtttcagg accccggacgg cggattcgcg ctgcctccgc cgccgcgggg
 181 cagccgggg gcaggggagcc cagcgagggg cgccgcgtgg cgccgcatg ggactgcgc
 241 ggatccggtg acagcaggga gccaagcgcc cccggccctg agcgcgttt ctccgggggg
 301 cctcgcgcctc ctgctcgccg gcccggggct cctgcctccgg ttgcgtggcc tggtgtggc
 361 tgccgcgcgc gcccaggata tcgtccggcgc ccgcgcgcgc gcccggggag cggccgtgc
 421 gagccgcgcgc gcccaggccg tggaggccgc cgcgcgagag ctgttcgagg cgtccgc
 481 cggggacgtg gaacgagtca agaggctgtt gacgcctgag aaggtaaca gcccgcac
 541 gccgggcagg aaatccaccc cgctgcactt cgccgcagggt ttggccgaa aagacgttagt
 601 tgaatatttgc ttccagaatgt gtgcataatgtt ccaagcactgtt gatgtgggg gccttattcc
 661 ttttcataat gcatgttctt ttggcatgtt tgaatgtgtt aatctccctt tgcgcacatgg
 721 tgcagacccc aatgtcgatgataattggaa ttatactctt ctccatgaag ctgcataatgg
 781 aggaaagatt gatgtttgc ttgtgttgc acagcatgtt gtcgagccaa ccatcgaaa
 841 tacatgttgc aggcacatgtt tggatttgc agatccatgtt gccaaggccag tgcctactgg
 901 tgaatataag aaatgttgc acatgttgc ttgtgttgc ggcataatgtt aaaaaatgtat
 961 ggctctactc acaccatcaa atgttgcactt ccacgcgtt gatggcagaa agtcaactcc
 1021 attacatttgc acgcaggatataa acatgttgc tgcataatgtt tgcacatgtt
 1081 agctgtatgc catgttgcataatgtt tgcgttgcataatgtt tgcacatgtt
 1141 ttgttgcattt gaaatgttgc acttttgttgc caatgttgc gtcgtgttgc atgttgc
 1201 ttgttgcataatgttgc ttcactccctt ttcactgaggc acgttgcataatgtt gtcacatgtt
 1261 ttttcataatgttgc agtattgttgc cagacccaaatgttgc acgttgcataatgtt gtcacatgtt
 1321 agacttgcgtt cccacaccac agttaaaaga aagatgttgc tatgttgcataatgtt aaggccactc
 1381 ttgttgcataatgttgc gtcgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1441 aatgttgcataatgttgc ttcacatgttgc ttttcataatgtt gtcacatgtt
 1501 tccatatcccccaaaaatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1561 tggatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1621 ttttcataatgttgc ttttcataatgtt gtcacatgtt
 1681 gacatgttgc ttttcataatgtt gtcacatgtt
 1741 ctatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1801 tggatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1861 acaatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1921 tcacatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 1981 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2041 taaatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2101 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2161 acatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2221 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2281 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2341 gatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2401 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2461 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2521 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2581 ttttcataatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2641 aatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2701 aatgttgc acatgttgc ttttcataatgtt gtcacatgtt
 2761 gacatgttgc acatgttgc ttttcataatgtt gtcacatgtt

U.S. Patent

Oct. 14, 2014

Sheet 17 of 20

US 8,859,562 B2

2821 tggagaaggccaggagcca ctgcagatgc tctcttca ggtccatcta gcccatcaag
 2881 ctttctgca gcccggcgtt gacaactt atctgggagt tttcagaac tgcttcagt
 2941 agtttgtca agtggaaacag agggtcttc cagttggag aaaaaggagg ttccaggagt
 3001 agattttagc ataactcaat tcgtaaggaa tcttggactt gggcaccaa tggatataatt
 3061 tgagagagaa cagatcacctt tgatgttatt agtgatgtt gggcacaagg agctgaagga
 3121 gattggaaatc aatgtttatc gacatagggca caaactaatt aaaggagtgc agagacttat
 3181 ctccggacaa caaggcttta accccatattt aacttgaac accctctggta gtggaaacaaat
 3241 tttatagat ctgtctctg atgataaaga gtttcgtt gttggagaaag agatgcaaaag
 3301 tacagtttca gagcacaggatggggca tgcaggggaa atcitaaca gatacaatatt
 3361 tctcaaggattt cagaagggtt gtaacaagaa actatggaa agatacaccc accggagaaaa
 3421 agaaggtttctt gaagaaaacc acaaccatgc caatgaacga atgttatttc atgggtctcc
 3481 tttgtgaat gcaattatcc acaaaggctt tgatgaaagg catgttaca taggtgttat
 3541 gtttggagctt ggcattttttt ttgcgtggaaa ctcttccaa agcaatcaat atgtatattt
 3601 aattggaggtt ggtactgggtt gttcaggatca caaagacaga ttttttaca ttggccacag
 3661 gcagctgcctt tttggccggg taaccttggg aaagtcttc ctgcaggatca gtgcataat
 3721 aatggccatcat ttcctccat gtcatcaatc agtcaatgtt agggccatgtt taaatggct
 3781 agcatttagttaatgtttaatgtttaatgtttaatgtttaatgtttaatgtttaatgtttaatgtt
 3841 ttaccatgtt atgaggctgtt aaggatgtt cgtatggatataatgtttaatgtttaatgtt
 3901 attccactga acctaaaatc atcaaaggcag cagtggctc tacgttttac ttcccttgc
 3961 aaaaaaaaaatc atcttgcctt caggccctgtt gcaaaaggat aaaaatgttga acgaaggat
 4021 acattctgac ttgataaagg tttataatgtt tacatgtttt tttttttttt
 4081 tcagcaattt aacagatgcctt atcccggtt aaactgggtt gtctgtacta aattataaac
 4141 agagtttaact tgaacctttt atatgtttaatgtt caattgttca aacaaactgtt aatggccctca
 4201 acagaactaa ttttactaat acaatactgtt gttttttttttaatgtttaatgtttaatgtt
 4261 acaatitcat tttttttttttaatgtttaatgtttaatgtttaatgtttaatgtttaatgtt
 4321 ttgttt
 4381 attgttcatc tataatctat ttatcatgtt catgtttagtggatgttttttttttttttttttttt
 4441 agaggctatgtt ttcagttttt agttggggaaa gatgttgc tcaatgtttaatgtttaatgtt
 4501 ggagcccttta tctgtcatttta gaaatcttc tcaatgtttaatgtttaatgtttaatgtt
 4561 ttt
 4621 gtcctgatca ctaagaaggccctttaatgtttaatgtttaatgtttaatgtttaatgtt
 4681 ttt
 4741 atcttgcgtt tgaacaatgtt ttt
 4801 tccagggttt
 4861 aaaggggaaa aaaaaaaaaatc caaacaggac tgggttttttttttttttttttttttttttttt
 4921 tcccttt
 4981 aacttaatccccccca agaactataaa aatgtttagttt ttttttttttttttttttttttttttt
 5041 caagtgcgtt gaaacagggtt ttt
 5101 attt
 5161 agtataatgtt ttt
 5221 ttccaggaaatgtt ttt
 5281 ttt
 5341 atgaggacat ttt
 5401 ttt
 5461 ttt
 5521 attatgttca ttt
 5581 taataatt
 5641 atatgttca ttt
 5701 ttt
 5761 agtgaatgtt ttt

Figure 13 (continued)

U.S. Patent

Oct. 14, 2014

Sheet 18 of 20

US 8,859,562 B2

5821 aaactgtgtt attttatctta aaccattgct taatgagtgt gttttccat gaatgaatat
5881 accgtgggtc atatgttagc atggcagcat tttcagatag cttttgtttt gttgggaagt
5941 tggggttttgg gggggagggg gagtattagt acgttgcattt gaatagccta cttataatg
6001 atgggaatgc ttttcctttt gttttggat tttttttttt gaagtgaaat ttaactttt
6061 gtgccagtag tactattata cccatctca gtgtctact tgtactgtat caaattccat
6121 accctcattt aattcitaat aaaactgttc acttgaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa
6181 aaaaaaaaaaaa

Figure 13 (continued)

U.S. Patent

Oct. 14, 2014

Sheet 19 of 20

US 8,859,562 B2

Figure 14

1 cgcccgcccc gccccgggg cagggaaagg ctaaaattacg gaattaccgc gagcaaggag
61 cgccgaatcg gggagcgtcc ggagcttagct ggatcctcta ggcaggatgg tgatggaat
121 ctttgc当地 tttgc当地 ttgttgc当地 agacttgc当地 ctttgc当地
181 gtc当地 acttgc当地 aatggccgg aaagttttcc ttgc当地 atccctactg
241 cacatata atcttagata atgc当地 tttgc当地 tttgc当地 atccctacta
301 aaagaaccac gt当地 atttgc当地 caaaaccagg aatctatca gagaaaaag
361 accttggat gtaaagaattt atgc当地 taagccctg gacatcacac cacccctg
421 tc当地 agggcg agc当地 tttgc当地 aatgttgc当地 agaaggctca tgccggaca
481 ggaggaagac acttgc当地 tttgc当地 tttgc当地 aatgttgc当地
541 tc当地 caagat ttgttgc当地 caaaatataa ctttgc当地 aatgttgc当地
601 cc当地 agact gt当地 tttgc当地 agt当地 ctttgc当地 tttgc当地
661 gataccctca ctttgc当地 tttgc当地 catggagact agaagacact
721 gaaaacccctca gaagatgcaat ttgttgc当地 tttgc当地 aatgttgc当地
781 aggatttca ctaagagaac atttc当地 accc tttgc当地 aatgttgc当地
841 gcaagcatttgc当地 tttgc当地 aatgttgc当地 ttcaagcact
901 tttagtagag atgatttggg ctttgc当地 gggccaccctg
961 agt当地 acagg atttc当地 acgttgc当地 caaggc当地
1021 ggc当地 ctttgc当地 aaaaatgggaa
1081 ctttgc当地 ctttgc当地 aatgttgc当地
1141 gaaagc当地 ctttgc当地 aatgttgc当地
1201 caaaaccaccc ctttgc当地 tttgc当地
1261 ttttgc当地 aatgttgc当地
1321 taagcccaat ttgttgc当地 tttgc当地
1381 gtttttgc当地 aatgttgc当地 atgttgc当地
1441 ctttgc当地 ttttgc当地
1501 aagaacagac
1561 tatcaacttgc当地
1621 agccctgg
1681 aggttgc当地
1741 ttttgc当地
1801 catgttgc当地
1861 ctttgc当地
1921 ttccagc当地
1981 ttttgc当地
2041 ctttgc当地
2101 ctttgc当地
2161 gtttgc当地
2221 gtttgc当地
2281 ttttgc当地
2341 ttttgc当地
2401 ttttgc当地
2461 gtttgc当地
2521 gtttgc当地
2581 gtttgc当地
2641 ttttgc当地
2701 ttttgc当地

U.S. Patent

Oct. 14, 2014

Sheet 20 of 20

US 8,859,562 B2

2761 ttccatggag ggtgtgacat tcttgcaga caggcaaatc accttgcatt cgctgtcc
 2821 gggtggtag aagoagaaag taaaatattt ccagtggc acaggataca aggagatatt
 2881 ttcgatccat aagcatatca caagcaatac cacggcagca gagttcatca tgtctgcc
 2941 acctaccatg gggAACACAG acttctggaa aacactccga tatcttagct tattgtacc
 3001 tgctcgaggg tcacggaca ttccttgggt gtctgtggg caccctccagg atgagagc
 3061 gacattacag ctctgtgaaga ggagccccc gcacaccagg tttatcgcc tgggttatcg
 3121 ttctacagca aatcgtaacg tttaaggat ttgtccca gtttgtgcg ggttatttga
 3181 atattttaat gaaaaatcca agcatatgtt gggaaacag atagaagacc aaatgacc
 3241 gctatgtctt ccggatgtcc actctgtctc cgtcaatgg cagcaactca atccagatgc
 3301 gccccggccc ctgcaggccc cagcccaagggt gccatcttg ttgcgaalgt atcgactcc
 3361 tgtctatggta ttcatcttc actgcacaca agcaactctg tgtgcactaa tcaagagaa
 3421 agaattttgtt acaatgggtt cgactactgtt gtttcagaag acaactggaa ctatgtcca
 3481 caagctggca gcccggatc taatcagaga ttatgaagat ggcaatcttc acgaaaaatga
 3541 aaccaggcat gagataaaaa aacaaaccc tttatcttgc attatataac tcagtaaaga
 3601 aaactcttc ataacacaaat ttacaaggctt ttggcagttt gggaaagg atgagaatga
 3661 gtgcctttt cctgatattc caaaaggttt tgaactttt gccaaagaag atgtatgtt
 3721 ctgccttac atgagctggc agggggagcc ccaagaagcc gtcaaggacc agtcttcc
 3781 agcatecttctt ggtggccag aattacgtt atccaaacga aaacatagga aaattccatt
 3841 ttccaaaaga aaaatggaaat tttttttttt tttttttttt tttttttttt tttttttttt
 3901 cttaggttta ctaccatgtt tttttttttt tttttttttt tttttttttt tttttttttt
 3961 ggatttaaatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4021 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4081 ctatcttacc cccacttccccc ggcgttccatccatccatccatccatccatccatccatcc
 4141 tcaggtagt agtttcgggtt cttttttttt tttttttttt tttttttttt tttttttttt
 4201 ccaaggccctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4261 aggacccccc cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4321 attaagetctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4381 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4441 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4501 accttccgea gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4561 ggctttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4621 aggcaggccccc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4681 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4741 agatgacagt atccctgtt tttttttttt tttttttttt tttttttttt tttttttttt
 4801 acactggccatccatccatccatccatccatccatccatccatccatccatccatccatccatcc
 4861 ctggaaaccc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4921 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 4981 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5041 agtgttcaaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5101 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5161 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5221 actccagccccc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5281 agtcaaatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5341 ataatagata attataatgtt tttttttttt tttttttttt tttttttttt tttttttttt
 5401 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 5461 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

Figure 14 (continued)

US 8,859,562 B2

1

**USE OF RNAI INHIBITING PARP ACTIVITY
FOR THE MANUFACTURE OF A
MEDICAMENT FOR THE TREATMENT OF
CANCER**

This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates the repair of DNA strand breaks in the treatment of certain forms of cancer in particular breast cancer.

Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic instability. It is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

Post transcriptional modification of nuclear proteins by poly(ADP-ribosylation) (PARP) in response to DNA strand breaks plays an important role in DNA repair, regulation of apoptosis, and maintenance of genomic stability.

Poly(ADP-ribose)Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using NAD⁺ as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA strand break (single strand or double strand) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see [3, 4] for reviews). The binding of PARP-1 to DNA strand breaks is believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased levels of SCE, micronuclei and tetraploidy (8-10). Genetic instability may also occur in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13).

These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to DNA strand breaks prevents the recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).

Studies based on treating cells with PARP inhibitors or cells derived from PARP-1 or PARP-2 knockout mice indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoicing (3, 4, 8-11, 19, 20, 47).

Inhibitors of PARP-1 activity have been used in combination with traditional anti-cancer agents such as radio therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however,

2

are known to cause damage and death to non cancerous or "healthy" cells and are associated with unpleasant side effects.

There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to PARP inhibitors as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally thereby indicating that PARP-1 is not essential for life. Thus, it could not be expected that cells would be sensitive to PARP inhibition.

According to a first aspect of the invention there is provided the use of an agent that inhibits the activity of an enzyme that mediates the repair of DNA strand breaks in the manufacture of a medicament for the treatment of diseases that are caused by a genetic defect in a gene that mediates homologous recombination.

In a further aspect the invention provides a method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene which mediates homologous recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent which inhibits the activity of an enzyme which mediates repair of DNA strand breaks or other lesions present at replication forks.

In a preferred aspect said enzyme is PARP. In a further preferred aspect said agent is a PARP inhibitor or an RNAi molecule specific to PARP gene.

In a further preferred aspect, the use is in the treatment of cancer.

Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

The specific sensitivity of HR defective tumours to PARP-1 inhibition means that normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemotherapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

In a further aspect, the invention further provides the use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

In another aspect the invention provides a method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.

By causing apoptosis in HR defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

Preferably, the HR defective cells are cancer cells.

Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

The term "cancer" or "tumour" includes lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. The cancer may also include skin, renal, liver, bladder or cerebral cancer. In a preferred aspect, the cancer is in a mammal, preferably human.

US 8,859,562 B2

3

The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1, BARD (see (2, 3, 5, 22-28) for reviews).

A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, these patients still maintain one functional allele. Thus, these patients develop normally and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour (1).

The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the cytotoxicity of the PARP inhibitor, NU1025, than wild type cells.

Thus in a preferred aspect, the invention provides the use of a PARP inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in HR, e.g. due to the loss of BRCA1 and/or BRCA2 expression.

The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR techniques, array techniques (29, 30) or using other screens known to the skilled person.

PARP inhibitors useful in the present invention may be selected from inhibitors of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 or tankyrase 2 (see 31 for a review). In a preferred embodiment, the PARP inhibitor useful in the present invention is an inhibitor of PARP-1 activity.

PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g. 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (TI1-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].

The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, topical routes among others. Carriers or diluents useful in the pharmaceutical composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

4

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

A therapeutically effective amount of the inhibitor is typically one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be up to 100 mg/kg, for example from 0.01 mg/kg to 50 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 5.0, 10, 15, 20 or 30 mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- 40 a) a nucleic acid sequence as represented by the sequence in FIG. 9, 10, 11, 12, 13 or 14 or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of FIG. 9, 10, 11, 12, 13 or 14 and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).

Recent studies suggest that RNAi molecules ranging from 100-1000 bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

More preferably said RNAi molecule according has a length of between 10 nucleotide bases (nb)-1000 nb. Even more preferably said RNAi molecule has a length of 10 nb; 20 nb; 30 nb; 40 nb; 50 nb; 60 nb; 70 nb; 80 nb; 90 nb; or 100 bp.

60 Even more preferably still said RNAi molecule is 21 nb in length.

Even more preferably still the RNAi molecule comprises the nucleic acid sequence aaa agc cau ggu gga gua uga (PARP-1)

65 Even more preferably still the RNAi molecule consists of the nucleic acid sequence aag acc aau cuc ucc agu uca ac (PARP-2)

US 8,859,562 B2

5

Even more preferably still the RNAi molecule consists of the nucleic acid sequence aag acc aac auc gag aac aac (PARP-3)

The RNAi molecule may comprise modified nucleotide bases.

Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*.

The present invention will now be described by way of example only with reference to the accompanying figures, wherein:

FIG. 1 is a graph demonstrating that HR deficient cells are hypersensitive to the toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese hamster cell lines AA8 (wild-type), irs1SF (deficient in HR[4]), CXR3 (irs1SF complemented with XRCC3 [2]), V79 (wild-type), irs1 (deficient in HR[5]) or irs1X2.2 (irs1 complimented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B) or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three experiments are shown. Colony outgrowth assay was used;

FIG. 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025 in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complimented with functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

FIG. 3 is a histogram showing the percentage of the cells in apoptosis following a 72 hour incubation with NU1025;

FIG. 4. (a) Western blot analysis of protein lysates isolated from MCF-7 (*p53^{wt}*) or MDA-MB-231 (*p53^{mut}*) breast cancer cells following 48 hours transfection with siRNA. (b) Colony outgrowth of siRNA-treated MCF-7 cells or (c) MDA-MB-231 cells following exposure to the PARP inhibitor NU1025. The means (symbols) and standard deviation (bars) of at least three experiments are shown.

FIG. 5. BRCA2 deficient cells fail to repair a recombination lesion formed at replication forks by inhibitors of PARP. (a) Visualization of double strand breaks (DSBs) in BRCA2 proficient or deficient cells following a 24-hour treatment with NU1025 (0.1 mM) by pulse-field gel electrophoresis. Hydroxyurea 2 mM was used as a positive control. (b) Visualisation of γ H2Ax foci in untreated V-C8+B2 and V-C8 cells. Number of cells containing γ H2Ax foci (c) or RAD51 foci (d) visualised in V-C8+B2 and V-C8 cells following a 24-hour treatment with NU1025 (10 μ M). The means (symbols) and standard errors (bars) of three to nine experiments are shown. (e) A suggested model for cell death induced in BRCA2 deficient cells.

FIG. 6. PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion, causing death in absence of BRCA2. (a) RT-PCR on RNA isolated from SW480SN.3 cells treated with BRCA2, PARP-1 and PARP-2 siRNA in combinations as shown for 48 hours. (b) Clonogenic survival following 48-hours depletion of BRCA2, PARP-1 and PARP-2. The means (symbols) and standard deviation (bars) of at least three experiments are shown. Two and three stars designate statistical significance in t-test $p<0.01$ and $p<0.001$, respectively. (c) Western blot for PARP-1 in SW480SN.3 cells treated with different siRNA.

FIG. 7. (a) Visualisation of PAR polymers in untreated and (b) thymidine treated V79 cells (5 mM for 24 hours). (c) Percentage cells containing >10 sites of PARP activity following treatment with hydroxyurea (0.2 mM) and thymidine (5 mM). At least 300 nuclei were counted for each treatment and experiment. (d) Survival of V-C8+B2 cells following co-treatment with hydroxyurea or (e) thymidine and NU1025 (10 μ M). (f) The activity of PARP was measured by the level of free NAD(P)H¹¹, following treatment with MMS, hydrox-

6

urea (0.5 mM) or thymidine (10 mM). The means (symbol) and standard deviation (error bars) from at least three experiments are depicted.

FIG. 8. (a) Visualisation of PAR polymers in untreated V-C8 and (b) V-C8+B2 cells. (c) Quantification of percentage cells containing >10 sites of PARP activity in untreated V-C8 and V-C8+B2 cells. (d) Level of NAD(P)H measured in untreated V-C8 and V-C8+B2 cells. Three stars designate $p<0.001$ in t-test. (e) Visualization of RAD51 and sites of PARP activity in V79 cells following a 24-hour thymidine treatment (5 mM). (f) A model for the role of PARP and HR at stalled replication forks.

FIG. 9 is the human cDNA sequence of PARP-1;

FIG. 10 is the human cDNA sequence of PARP-2;

FIG. 11 is the human cDNA sequence of PARP-3;

FIG. 12 is the human gDNA sequence of Tankyrase 1;

FIG. 13 is the human mRNA sequence of Tankyrase 2;

FIG. 14 is the human mRNA sequence of VPARP.

MATERIALS AND METHODS

Cytotoxicity of PARP Inhibitors to HR-Defective Cells: XRCC2, XRCC3 or BRCA2 Cell Culture

The irs1, irs1X2.1 and V79-4 cell lines were a donation from John Thacker [40] and the AA8, irs1SF and CXR3 cell lines were provided by Larry Thompson [41].

The VC-8, VC-8+B2, VC-8#13 were a gift from Małgorzata Zdziennicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetal bovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 μ g/mL) at 37° C. under an atmosphere containing 5% CO₂.

Toxicity Assay—Colony Outgrowth Assay

500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7-12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently counted.

Apoptosis Experiments

0.25 \times 10⁶ cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodine (PI) (ApoTarget, Biosource International) according to manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSort, 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

Immunofluorescence

Cells were plated onto coverslips 4 h prior to 24-h treatments as indicated. Following treatments the medium was removed and coverslips rinsed once in PBS at 37° C. and fixed as described elsewhere [2]. The primary antibodies and dilutions used in this study were; rabbit polyclonal anti PAR (Trevigen; 1:500), goat polyclonal anti Rad51 (C-20, Santa Cruz; 1:200) and rabbit polyclonal anti Rad51 (H-92, Santa Cruz; 1:1000). The secondary antibodies were Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed; 1:500), Alexa 555 goat anti-rabbit F(ab')₂IgG antibody (Molecular Probes; 1:500), Alexa 546 donkey anti-goat IgG antibody (Molecular Probes; 1:500) and Alexa 488 donkey anti-rabbit IgG antibody (Molecular Probes; 1:500). Antibodies were diluted in

US 8,859,562 B2

7

PBS containing 3% bovine serum albumin. DNA was stained with 1 µg/ml To Pro (Molecular Probes). Images were obtained with a Zeiss LSM 510 inverted confocal microscope using planapochromat 63X/NA 1.4 oil immersion objective and excitation wavelengths 488, 546 and 630 nm. Through focus maximum projection images were acquired from optical sections 0.50 µm apart and with a section thickness of 1.0 µm. Images were processed using Adobe PhotoShop (Abacus Inc). At least 300 nuclei were counted on each slide and those containing more than 10 RAD51 foci or sites of PARP activity were classified as positive.

PARP Activity Assays

A water-soluble tetrazolium salt (5 mM WST-8) was used to monitor the amount of NAD(P)H through its reduction to a yellow coloured formazan dye[43]. 5000 cells were plated in at least triplicate into wells of a 96 well plate and cultured in 100 µl normal growth media for 4 h at 37° C. CK8 buffer (Dojindo Molecular Technology, Gaithersburg, USA), containing WST-8, was then added either with or without treatment with DNA damaging agents at concentrations indicated. Reduction of WST-8 in the presence of NAD(P)H was determined by measuring visible absorbance (OD₄₅₀) every 30 min. A medium blank was also prepared containing just media and CK8 buffer. Changes in NAD(P)H levels were calculated by comparing the absorbance of wells containing cells treated with DNA damaging agents and those treated with DMSO alone. Alternately relative levels of NAD(P)H in different cells lines were calculated after 4 h incubation in CK8 buffer.

The ability of NU1025 to inhibit PARP-1 activity was also assayed in permeabilised cells using a modification of the method of Halldorsson et al [44], and described in detail elsewhere [45]. Briefly: 300 µl of NU1025-treated (15 min) permeabilised cells were incubated at 26° C. with oligonucleotide (final conc. 2.5 µg/ml), 75 µM NAD+[³²P] NAD (Amersham Pharmacia, Amersham, UK) in a total volume of 400 µl. The reaction was terminated after 5 min by adding ice cold 10% TCA 10% Na Ppi for 60 min prior to filtering through a Whatman GF/C filter (LabSales, Maidstone, UK), rinsed 6x with 1% TCA 1% NaPPI, left to dry and incorporated radioactivity was measured to determine PARP-1 activity. Data are expressed as pmol NAD incorporated/10⁶ cells by reference to [³²P] NAD standards.

Pulse-Field Gel Electrophoresis

1.5×10⁶ cells were plated onto 100 mm dishes and allowed 4 h for attachment. Exposure to drug was for 18 h after which cells were trypsinised and 10⁶ cells melted into each 1% agarose insert. These inserts were incubated as described elsewhere (8) and separated by pulse-field gel electrophoresis for 24 h (BioRad; 120° angle, 60 to 240 s switch time, 4 V/cm). The gel was subsequently stained with ethidium bromide for analysis.

siRNA Treatment

Predesigned BRCA2 SMARTpool and scrambled siRNAs were purchased (Dharmacon, Lafayette, Colo.). 10000 cells seeded onto 6 well plates and left over night before transfected with 100 nM siRNA using Oligofectamine Reagent (Invitrogen) according to manufacturers instructions. Cells were then cultured in normal growth media for 48 h prior to trypsinisation and replating for toxicity assays. Suppression of BRCA2 was confirmed by Western blotting (as described previously [46]) of protein extracts treated with siRNA with an antibody to BRCA2 (Oncogene, Nottingham, UK).

EXAMPLES

Homologous Recombination Deficient Cells are Hypersensitive to PARP-1 Inhibition

To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on

8

the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., irs1SF which is defective in XRCC3 or irs1 which is defective in XRCC2 [see Table 1] were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (FIG. 1). The sensitivity in irs1SF cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional XRCC3 gene (CXR3). Similarly, the sensitivity in irs1 cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional XRCC2 gene (irs1X2.2).

BRCA2 Deficient Cells are Hypersensitive to PARP-1 Inhibition

The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (FIG. 2). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct consequence of loss of the BRCA2 function.

To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (FIG. 3).

BRCA2 Deficient Breast Cancer Cells are Hypersensitive to PARP-1 Inhibition

It was examined whether the MCF7 (wild-type p53) and MDA-MB-231 (mutated p53) breast cancer cell lines displayed a similar sensitivity to NU1025 upon depletion of BRCA2. It was found that PARP inhibitors profoundly reduced the survival of MCF7 and MDA-MB-231 cells only when BRCA2 was depleted with a mixture of BRCA2 siRNA (FIG. 4). This shows that BRCA2 depleted breast cancer cells are sensitive to PARP inhibitors regardless of p53 status.

BRCA2 Deficient Cells Die from PARP-1 Inhibition in Absence of DNA Double-Strand Breaks (DSBs) but in Presence of γH2Ax

HR is known to be involved in the repair of DSBs and other lesions that occur during DNA replication [2]. To determine whether the sensitivity of BRCA2 deficient cells is the result of an inability to repair DSBs following NU1025 treatment, the accumulation of DSBs in V79 and V-C8 cells was measured following treatments with highly toxic levels of NU1025. It was found that no DSBs were detectable by pulsed field gel electrophoretic analysis of DNA obtained from the treated cells (FIG. 5A), suggesting that low levels of DSBs or other recombinogenic substrates accumulated following PARP inhibition in HR deficient cells, which trigger γH2Ax FIG. 5B).

The reason why BRCA2 deficient cells die following induction of these recombinogenic lesions is likely to be due to an inability to repair such lesions. To test this, the ability of BRCA2 deficient V-C8 cells and BRCA2 complemented cells to form RAD51 foci in response to NU1025 was determined. It was found that RAD51 foci were indeed induced in V-C8+B2 cells following treatment with NU1025 (statistically significant in t-test p<0.05; FIG. 5D). This indicates that the recombinogenic lesions trigger HR repair in these cells allowing them to survive. In contrast, the BRCA2 deficient V-C8 cells were unable to form RAD51 foci in response to NU1025 treatment (FIG. 5D) indicating no HR, which would leave the recombinogenic lesions unrepaired and thus cause cell death.

US 8,859,562 B2

9

PARP-1 and Not PARP-2 is Important in Preventing Formation of a Recombinogenic Lesion

There are two major PARPs present in the nucleus in mammalian cells, PARP-1 and PARP-2 and all reported PARP inhibitors inhibit both. In order to distinguish which PARP was responsible for the effect, we tested if the absence of PARP-1 and/or PARP-2 results in accumulation of toxic lesions, by depleting these and BRCA2 with siRNA in human cells (FIG. 6a). We found that the clonogenic survival was significantly reduced when both PARP-1 and BRCA2 proteins were co-depleted from human cells (FIG. 6b). Depletion of PARP-2 with BRCA2 had no effect on the clonogenic survival and depletion of PARP-2 in PARP-1 and BRCA2 depleted cells did not result in additional toxicity. These results suggest that PARP-1 and not PARP-2 is responsible for reducing toxic recombinogenic lesions in human cells. The cloning efficiency was only reduced to 60% of control in PARP-1 and BRCA2 co-depleted cells, while no HR deficient cells survived treatments with PARP inhibitors. This is likely to do with incomplete depletion of the abundant PARP-1 protein by siRNA (FIG. 6c), which might be sufficient to maintain PARP-1 function in some of the cells.

PARP-1 is Activated by Replication Inhibitors

HR is also involved in repair of lesions occurring at stalled replication forks, which may not involve detectable DSBs [2]. To test if PARP has a role at replication forks, PARP activation in cells treated cells with agents (thymidine or hydroxyurea) that retard or arrest the progression of DNA replication forks was examined. Thymidine depletes cells of dCTP and slows replication forks without causing DSBs. Hydroxyurea depletes several dNTP and block the replication fork, which is associated with the formation of DSBs at replication forks [2]. Both of these agents potently induce HR [2]. V79 hamster cells treated for 24 hours with thymidine or hydroxyurea were stained for PAR polymers. This revealed a substantial increase in the number of cells containing sites of PARP activity (FIG. 7C). This result suggests a function for PARP at stalled replication forks. It was also shown that inhibition of PARP with NU1025 enhances the sensitivity to thymidine or hydroxyurea in V-C8+B2 cells (FIG. 7D,E). This result suggests that PARP activity is important in repair of stalled replication forks or alternatively that it prevents the induction of death in cells with stalled replication forks.

PARP is rapidly activated at DNA single-strand breaks (SSB) and attracts DNA repair enzymes [3-6]. Methyl-methane sulphonate (MMS) causes alkylation of DNA, which is repaired by base excision repair. PARP is rapidly activated by the SSB-intermediate formed during this repair, which depletes the NAD(P)H levels (FIG. 7F). We found that the activation of PARP and reduction of NAD(P)H levels is much slower following thymidine or hydroxyurea treatments. This slow PARP activation can be explained by the indirect action of thymidine and hydroxyurea and the time required to accumulate stalled replication forks as cells enter the S phase of the cell cycle.

PARP-1 and HR Have Separate Roles at Stalled Replication Forks

The number sites of PARP activity in untreated BRCA2 deficient V-C8 cells was determined. It was found that more V-C8 cells contain sites of PARP activity compared to V-C8+B2 cells (FIG. 8A,B,C). Also, the V-C8 cells have lower free NAD(P)H levels than the corrected cells (FIG. 8D), as a likely result of the increased PARP activity. Importantly these sites of PARP activity do not overlap with RAD51 foci (FIG. 8E).

The results herein suggest that PARP and HR have separate roles in the protection or rescue of stalled replication forks (FIG. 8F). A loss of PARP activity can be compensated by

10

increased HR while a loss of HR can be compensated by increased PARP activity. However, loss of both these pathways leads to accumulation of stalled replication forks and to death, as in the case of PARP inhibited BRCA2 deficient cells.

As shown in the model outlined in FIG. 8F PARP and HR have complementary roles at stalled replication forks. (i) Replication forks may stall when encountering a roadblock on the DNA template. In addition, they may also stall temporarily, due to lack of dNTPs or other replication co-factors. (ii) PARP binds stalled replication forks or other replication-associated damage, triggering PAR polymerization. Resulting negatively charged PAR polymers may protect stalled replication forks, by repelling proteins that normally would process replication forks (e.g., resolvases), until the replication fork can be restored spontaneously when dNTPs or other co-factors become available. Alternatively, PAR polymers or PARP may attract proteins to resolve the replication block by other means. (iii) In absence of PARP activity, HR may be used as an alternative pathway to repair stalled replication forks. This compensatory model explains the increased level of HR and RAD51 foci found in PARP deficient cells³⁻⁵ and higher PARP activity found in HR deficient cells (i.e. V-C8). Spontaneous replication blocks/lesions are only lethal in the absence of both PARP and HR.

TABLE 1

Genotype and origin of cell lines used in this study.				
Cell line	Genotype	Defect	Origin	Reference
AA8	Wt	Wt	CHO	[41]
irs1SF	XRCC3 ^{-/-}	XRCC3 ^{-/-} , deficient in HR	AA8	[41]
CXR3	XRCC3 ^{-/-} +	Wt	irs1SF	[41]
	hXRCC3			
V79-4	Wt	Wt	V79	[40]
irs1	XRCC2 ^{-/-}	XRCC2 ^{-/-} , deficient in HR	V79-4	[40]
irs1X2.2	XRCC2 ^{-/-} +	Wt	irs1	[40]
	hXRCC2			
V79-Z	Wt	Wt	V79	[42]
VC8	BRCA2 ^{-/-}	BRCA2 ^{-/-} , deficient in HR	V79-Z	[42]
VC8#13	BRCA2 ^{-/-} +	Wt	VC8	[42]
	hBRCA2			
VC8 + B2	BRCA2 ^{-/-} +	Wt	VC8	[42]
	hBRCA2			

REFERENCES

- A. R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2, *Cell* 108 (2002) 171-182.
- C. Lundin, K. Erixon, C. Arnaudeau, N. Schultz, D. Jenseen, M. Meuth and T. Helleday Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells, *Mol Cell Biol* 22 (2002) 5869-5878.
- D. D'Amours, S. Desnoyers, I. D'Silva and G. G. Poirier Poly(ADP-ribosylation) reactions in the regulation of nuclear functions, *Biochem J* 342 (1999) 249-268.
- Z. Herceg and Z. Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, *Mutat Res* 477 (2001) 97-110.
- T. Lindahl, M. S. Satoh, G. G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose)polymerase induced by DNA strand breaks, *Trends Biochem Sci* 20 (1995) 405-411.
- M. S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA repair, *Nature* 356 (1992) 356-358.

US 8,859,562 B2

11

- [7] S. Shall and G. de Murcia Poly(ADP-ribose)polymerase-1: what have we learned from the deficient mouse model?, *Mutat Res* 460 (2000) 1-15.
- [8] Z. Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E. F. Wagner PARP is important for genomic stability but dispensable in apoptosis, *Genes Dev* 11 (1997) 2347-2358.
- [9] C. M. Simbulan-Rosenthal, B. R. Haddad, D. S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H. M. Young, Z. Q. Wang, T. Ried and M. E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, *Proc Natl Acad Sci USA* 96 (1999) 13191-13196.
- [10] J. M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F. J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose)polymerase in recovery from DNA damage in mice and in cells, *Proc Natl Acad Sci USA* 94 (1997) 7303-7307.
- [11] F. d'Adda di Fagagna, M. P. Hande, W. M. Tong, P. M. Lansdorp, Z. Q. Wang and S. P. Jackson Functions of poly(ADP-ribose)polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.
- [12] E. Samper, F. A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J. C. Cigudosa, G. de Murcia and M. A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose)polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.
- [13] C. Morrison, G. C. Smith, L. Stingl, S. P. Jackson, E. F. Wagner and Z. Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.
- [14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J. M. De Murcia A dominant-negative mutant of human poly(ADP-ribose)polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci USA* 92 (1995) 4753-4757.
- [15] J. H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosylation) potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.
- [16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells *in vivo* in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.
- [17] A. S. Waldman and B. C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.
- [18] A. Semionov, D. Cournoyer and T. Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.
- [19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose)polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.
- [20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose)polymerase-1, *Biochemistry* 39 (2000) 7559-7569.

12

- [21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose)polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.
- [22] T. Lindahl and R. D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.
- [23] K. W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.
- [24] D. D'Amours and S. P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.
- [25] A. D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.
- [26] S. P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.
- [27] R. Kanaar, J. H. Hoeijmakers and D. C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.
- [28] D. C. van Gent, J. H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.
- [29] S. L. Neuhausen and E. A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.
- [30] G. Kuperstein, W. D. Foulkes, P. Ghadirian, J. Hakimi and S. A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.
- [31] A. Chiarugi Poly(ADP-ribose)polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.
- [32] C. R. Calabrese, M. A. Batey, H. D. Thomas, B. W. Durkacz, L. Z. Wang, S. Kyle, D. Skalitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A. H. Calvert, Z. Hostomsky, D. R. Newell and N. J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose)Polymerase-1 inhibitors: Chemopotentiation and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.
- [33] D. Ferraris, Y. S. Ko, T. Pahutski, R. P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M. X. Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L. P. Williams, Q. Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5-[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.
- [34] K. J. Dillon, G. C. Smith and N. M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.
- [35] A. J. Pierce, R. D. Johnson, L. H. Thompson and M. Jaslin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.
- [36] R. D. Johnson, N. Liu and M. Jaslin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.
- [37] G. M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J. C. Hoflack, P. Rong, M. ApSimon, J. B. Kirkland and G. G. Poirier Complete inhibition of poly(ADP-ribose)polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.
- [38] R. J. Griffin, S. Srinivasan, K. Bowman, A. H. Calvert, N. J. Curtin, D. R. Newell, L. C. Pemberton and B. T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.

US 8,859,562 B2

13

- [39] S. Boulton, L. C. Pemberton, J. K. Porteous, N. J. Curtin, R. J. Griffin, B. T. Golding and B. W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose)polymerase inhibitors, Br J Cancer 72 (1995) 849-856.
- [40] C. S. Griffin, P. J. Simpson, C. R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, Nat Cell Biol 2 (2000) 757-761.
- [41] R. S. Tebbs, Y. Zhao, J. D. Tucker, J. B. Scheerer, M. J. Siciliano, M. Hwang, N. Liu, R. J. Legerski and L. H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, Proc Natl Acad Sci USA 92 (1995) 6354-6358.
- [42] M. Kraakman-van der Zwet, W. J. Overkamp, R. E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P. P. van Buul, A. Errami, R. T. Tan, N. G. Jaspers, S. K. Sharan, R. Kanaar and M. Z. Zdienicka Brca2 (XRCC11) deficiency results in radioresistant DNA

14

- synthesis and a higher frequency of spontaneous deletions, Mol Cell Biol 22 (2002) 669-679.
- [43] J. Nakamura, S. Asakura, S. D. Hester, G. de Murcia, K. W. Caldecott and J. A. Swenberg Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time, Nucleic Acids Res 31 (2003) e104.
- [44] H. Halldorsson, D. A. Gray and S. Shall Poly(ADP-ribose)polymerase activity in nucleotide permeable cells, FEBS Lett 85 (1978) 349-352.
- [45] K. Grube, J. H. Kupper and A. Burkle Direct stimulation of poly(ADP ribose)polymerase in permeabilized cells by double-stranded DNA oligomers, Anal Biochem 193 (1991) 236-239.
- [46] C. Lundin, N. Schultz, C. Amaudeau, A. Mohindra, L. T. Hansen and T. Helleday RAD51 is Involved in Repair of Damage Associated with DNA Replication in Mammalian Cells, J Mol Biol 328 (2003) 521-535.
- [47] Schreider et al., Journal of Biological Chemistry 277: 23028-23036 (2002).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 9

<210> SEQ ID NO 1
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

aaaagccaug guggaguaug a

21

<210> SEQ ID NO 2
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

aagaccaaauuc ucuccaguuc aac

23

<210> SEQ ID NO 3
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

aagaccaaaca ucgagaacaa c

21

<210> SEQ ID NO 4
<211> LENGTH: 5468
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

cggccgcgcca gccccggggg caggaaagc ctaaattacg gaattaccgc gagcaaggag 60
cgcggaatcg gggagcgatcc ggagctgatct ggatccctta ggcaggatgg tggatggaaat 120
ctttgcaaat tgttatcttct gtttgaaagt gaagtacttta cctcagcgc agaagaaaaaa 180
gctacaaact gacattaagg aaaatggcg aaagtttcc ttttcgttaa atcctcagtg 240
cacacatata atcttagata atgctgtatgt tctgagtcag taccaactga attcttatcca 300
aaagaaccac gttcatatgt caaacccaga ttttatatgg aaatctatca gagaaaagag 360
actcttggat gtaaagaatt atgatcccta taagcccctg gacatcacac cacccctgaa 420

US 8,859,562 B2

15**16**

-continued

tcagaaggcg	agcagttctg	aagtgaaaac	agaaggctta	tgcggacata	gtgccacaga	480
ggaggaagac	actgttggaaac	tcacttgatgtt	tggatgtca	aatgttggaa	ttccatct	540
tcctcaagat	tttgaagttt	caaaatataa	cacccggag	aaagtggaa	tggaggagg	600
ccaggaagct	gtgggtgtgg	agtttcgtt	tccggacat	tccaggact	gtccatct	660
gatattccca	cacttcctcc	tggatgtatgg	catggagact	agaagacagt	ttgtatataa	720
gaaaacctct	gaagatgcaa	gtgaataactt	tgaaaattac	attgaagaac	tgaagaaaca	780
aggatttcta	ctaagagaac	atttcacacc	tgaagcaacc	caatttagcat	ctgaacaatt	840
gcaagcattt	cttttggagg	aagtcatgaa	ttcaagcaact	ctgagccaa	agggtggcga	900
tttagtagag	atgatttggg	cagaggccct	gggcccacct	gaacacatgc	ttctcaagcc	960
agtgaacagg	atttgcctca	acgtgtgg	caaggcagag	gggatttcc	ttcttagtaaa	1020
ggcagcactg	aaaaatggag	aaacagcaga	gcaattgcaa	aagatgtatg	cagatgttta	1080
cagactgata	ccttcacaaag	gcacaatgccc	caaagaagtg	aacctggac	tattggctaa	1140
gaaaggcagac	ctctgccagc	taataagaga	catggtaat	gtctgtgaaa	ctaatttgc	1200
caaaccacac	ccaccatccc	tggccaaata	ccgagcttt	aggtgcaaaa	ttgagoatgt	1260
tgaacagaat	actgaagaat	tttcagggt	tagaaaagag	gttttgccaga	atcatcacag	1320
taagagccca	gtggatgtct	tgcagatatt	taggttggc	agagtgaatg	aaaccacaga	1380
gttttgagc	aaacttggta	atgtgaggcc	cttggatgt	ggttctct	tacaaaacat	1440
cgtggaaatc	tttgtgtcgag	gggttgcctt	acccaaagta	gtggaaagatc	gtgggtgtca	1500
aagaacagac	gtggaaacc	ttggaaagtgg	gatttatttc	agtgttgc	tcaatgtaca	1560
tatcaagtac	tcacacccgg	gagagacaga	tggcaccaga	ctcctgtca	tttgtgacgt	1620
agccctcgga	aagtgtatgg	acttacatga	gaaggactt	tccttaactg	aagcaccacc	1680
aggttacgac	agtgtgcgt	gagtttca	aacagcctt	gtcaccacag	acttttggag	1740
tgtatgtt	gttgtctata	aaaccaatca	ggttaaaatg	aaatataatta	ttaaattttc	1800
catgcctgga	gatcagataa	aggacttca	tccttagtgc	catactgat	tagggata	1860
cagacctgag	tttcaaattt	tttcaaagg	tgaagattac	cagttaccag	atgccaac	1920
ttccagcagc	accaaggcg	gectccagg	tgcttctgg	aacttggtc	ctctggagga	1980
tgtccacatc	aaagggagaa	tcatagacac	tgtagccag	gtcattttt	ttcagacata	2040
cacaataaaa	agtacacgtgc	ccattgggg	aaaatatac	tttcccttgg	atgacaaggc	2100
cgctgtgtgt	ggcttcgaag	ccttcataa	tggaaagcac	atagttggag	agattaaaga	2160
gaaggaagaa	gcccagcaag	agtacctaga	agccgtgacc	cagggccat	gctgttac	2220
gatgagtcag	gatgttccgg	acgtttttac	tgtaaatgtt	ggaaacttac	ccccataggc	2280
taaggttctt	ataaaaaat	cctacatcac	agaactcagc	atcctggca	ctgttgggt	2340
cttttcatg	cccgccaccc	tagcaccct	gcaacaggac	aaggcttga	atgaaaac	2400
tcaggatata	gtagagaaga	tttgtataaa	agaaatagga	acaaagcaaa	gcttctttt	2460
gactatgtct	attgagatgc	cgtacgtat	tgaatttatt	ttcagtatgc	ctcatgact	2520
gaaacaaaag	cgcacagact	gcaagctgt	cattagcacc	atggaaaggc	gctccttgc	2580
cagcagtgg	ttttctctcc	acatcggtt	gtctgtgc	tatctccaa	aatgtgggt	2640
tgaaaaaacat	ccagaaaaag	aaagcgaggc	ttgcatgctt	gtcttcaac	ccgatctcg	2700
tgtcgaccc	cctgaccc	ccatgagag	cgaagtgtt	atttgcctt	actgtccag	2760

US 8,859,562 B2

17**18**

-continued

ttccatggag ggtgtgacat tcttgcaga caggaaatc gccttgcatg cgctgtcctt	2820
ggtgggtgag aagcagaaaag taaatattat ccagttcgcc acaggatata aggagatatt	2880
ttcgtatcct aagcatatca caagcaatac cgccgcagca gagttcatca tgtctgccac	2940
acctaccatg gggAACACAG acttctggaa aacactccga tatcttagct tattgtaccc	3000
tgctcgaggg tcacggaca tcttccttgt gtctgtggt cacccagg atgagagcct	3060
gacattacag ctctgtgaaaa ggagccgccc gcacaccagg ttattcgct gcggtatcg	3120
ttctacagca aatcgtcactg tcttaaggat tttgtcccag tgtggcg gagtattga	3180
atattttaat gcaaaatcca agcatagttt gaaaaacag atagaagacc aaatgaccag	3240
gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc	3300
gcccggggcc ctgcaggccc cagccccagg gccatcctt tttcgcaatg atcgactcct	3360
tgtctatggg ttcatcctc actgcacaca ggcaactctg tgtgcactaa ttcaagagaa	3420
agaattttgt acaatgggtt cgactactga gtttcagaag acaactggaa ctatgtatcca	3480
caagctggca gcccggagtc taatcagaga ttatgaagat ggcatttcc acgaaaatga	3540
aaccagtcat gagatgaaaa aacaaacacctt gaaatctctg attattaaac tcagtaaaga	3600
aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaaggg atgagaatga	3660
gtcacctttt cctgtatattc caaaagtttc tgaacttatt gccaaagaag atgttagactt	3720
cctgccttac atgagctggc agggggaaacc ccaagaagcc gtcaggaacc agtctttttt	3780
agcatcctct gagtggccag aattacgtt atccaaacga aaacatagga aaattccatt	3840
ttccaaaaga aaaatggaaat tatctcagcc agaagttct gaagattttg aagaggatgc	3900
cttaggtgtt ctaccagctt tcacatcaaa tttggAACGT ggacgtgtgg aaaagctatt	3960
gatTTTAACT tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaagt	4020
cagtccatgg gaaacatcta cttctagctt ttttcctatt ttggctccgg ccgttggttc	4080
ctatcttacc ccgactaccc ggcgtcagac ttctgtttcc ttgtcttttgc cctcatatcg	4140
tcaggttagct agtttcgggtt cagctgtcc tcccgacacag tttgtatgcat ctcaattcag	4200
ccaaggccct gtgcctggca cttgtgtga ctggatccca cagtcggcgt ttgtcccac	4260
aggacctccc cagaacccac cttctgcacc ctattgtggc attttttt cagggagctc	4320
attaagctct gcacagtctg ctccactgca acatcctggaa ggctttacta ccaggccttc	4380
tgcgtggcacc ttccctgagc tggattctcc ccagcttcat ttctcttcc ctacagaccc	4440
tgtatcccattc agaggatTTG ggtttatca tccctctgtt tactctctt ttcatTTCA	4500
accttccgca gccttttga ctgccaacct taggctgcca atggcctctg ctttacctga	4560
ggcttttgc agtcagttccc ggactacccc agtagatctc tgtcttctag aagaatccgt	4620
aggcagtctc gaaggaagtc gatgtctgtt ctttgccttt caaagttctg acacagaaag	4680
tgtatgacatc tcagaagttac ttcaagacag ctgtttttt caaataaaaat gtgatataaa	4740
agatgacagt atcccgtgt ttttggaaatg aaaagaagag gatgaaatag tgtgcacaca	4800
acactggcag gatgctgtgc cttggacaga actcctcagt ctacagacag aggatggctt	4860
ctggaaactt acaccagaac tgggacttat attaaatctt aatacaaatg gtttgacacag	4920
ctttcttaaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcttgc	4980
cctaattgcc acaatgctgg tactacaggattatc tattcgccacc aggttggaaa aagaggaaat	5040
agtgttcaaa tcactgtatga aaatggatga cccttctatt tccaggaata ttccctgggc	5100
ttttgaggca ataaagcaag caagtgtatg ggtaagaaga actgaaggac agtaccatc	5160

US 8,859,562 B2

19**20**

-continued

tatctgcccc cggcttgaac tggggaacgca ctgggactct gccaccaagc agttgtggg	5220
actccagccc ataaggactg tgtcccccttc tcatagagtc ctccattaca gtcaaggcta	5280
agtcaaatga aactgaattt taaactttt gcatgcttct atgtagaaaa taatcaaatg	5340
ataatagata cttataatga aacttcattt aggtttcatt cagtgttagca attactgtct	5400
ttaaaaatta agtggaaagaa gaattacttt aatcaactaa caagcaataa taaaatgaaa	5460
cttaaaat	5468

<210> SEQ ID NO 5
<211> LENGTH: 1910
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

ctagaattca gcggcccgctg aattcttaggc ggccgcggcgg cgacggagca ccggcgccgg	60
caggggcgaga gcattaaatg aaagcaaaag agttaataat ggcaacacgg ctccagaaga	120
ctctccctt gccaagaaaa ctctgtatgc ccagagacag gagtcgaaaa agatgcctgt	180
ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag	240
gtcatggccc agcaaaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaaagc	300
tcctgtggac ccagagtgtt cagccaaatggc ggggaaggct catgtgtatt gtgaaggaaa	360
tgtatgttat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta	420
tctgatttcag ctattagaag atgatgccca gaggaaacctc agtgtttggta tgagatgggg	480
cccgatgtggg aaaatgggac agcacagccct ggtggcttgc tcaggeaatc tcaacaaggc	540
caaggaaatc ttccagaaga aattccttgc caaaacgaaa aacaattttgg aagatcgaga	600
aagtttgag aaggtgcctg gaaaatatga tatgctacag atggactatg ccaccaatac	660
tcaggatgaa gaggaaacaa aaaaagagga atctcttaaa tctcccttgc agccagatgc	720
acagctagat ctccgggtac aggagttat aaagttgtatc tgtaatgttc aggccatggaa	780
agaaatgtatc atggaaatga agtataatac caagaaagcc ccacttggaa agctgacagt	840
ggcacaaatc aaggcagggtt accagtctct taagaagatt gaggattgtt ttccggctgg	900
ccagcatggaa cgagctctca tggaaagcatg caatgaattt tacaccaggaa ttccgcgttgc	960
ctttggactc cgtactccctc cactaatccg gacacagaag gaactgttc aaaaaataca	1020
attactatggat gctttggag acattgtatc tgctttaatc ctgggttttttgggggggggggg	1080
aagcccagaa cacccattgg accaacacta tagaaaccta cattgtgcct tgcccccctt	1140
tgaccatgaa agttacgatc tcaaagtgtt ttcccaggatc ctacaatctt cccatgttcc	1200
cacacacagc gactataccca tgacccctgtt ggatttttttgggggggggggggggggggggg	1260
gaaagaagcc ttccaggagg accttcataa caggatgtttt ctatggcatg gttccaggat	1320
gagtaactgg gtggaaatct tgagccatgg gcttcgaattt gcccaccctgg aagctcccat	1380
cacagggttac atgtttggga aaggaatctt ctttgcgttgc atgtttccca agagtgccaa	1440
ttactgtttt gcttctcgcc taaaatgtatc aggactgtttt ctcttatttcg aggttagtct	1500
aggtcagtgtt aatgtactac tagaggccaa tcctaaaggcc gaaggatgttgc ttcaaggttt	1560
acatagcacc aaggggctgg gcaagatggc tcccaatgtt gcccacttgc tcaccctgaa	1620
tgggagttaca gtgcattttt gaccaggaaatc tgacacagggaa attctgtatc cagatgttt	1680
taccctcaac tacaatgtatc atattgtata taaccccaac caggtccgttgc tgccgttcc	1740

US 8,859,562 B2

21**22**

-continued

tttaaagggtt cagtttaatt tccttcagct gtggtaatg ttgatcttaa ataaaccaga	1800
gatctgatct tcaagcaaga aaataagcg tgggtactt gtgaatttg tgatattta	1860
tgtataaaaa actgtacagg tctaaaaaaaaaaaaaaaaaaaaaaaa	1910
<210> SEQ ID NO 6	
<211> LENGTH: 2263	
<212> TYPE: DNA	
<213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 6	
tgggacttgt cgccctgactc ggccctgcccc agcctctgct tcaccccact ggtggccaaa	60
tagccatgt ctaatcccc acacaagctc atccccggcc tctgggattt tgggattc	120
tctccctaattc acgcctgatggaa gagttgttagt acctgggact gcccctggag	180
gcccacacaa ccaggccggg tggcagccag gacctctccc atgtccctgc ttttcttggc	240
catggcttca aagccgaagc cctgggtaca gactgaggc cctgagaaga agaaggccg	300
gcaggcagga agggaggagg acccccttccg ctccaccgct gaggccctca aggccatacc	360
cgcagagaag cgcataatcc gcgtggatcc aacatgttca ctcagcagca accccgggac	420
ccaggtgtat gaggactaca actgcacccct gaaccagacc aacatgaga acaacaacaa	480
caagttctac atcatccagc tgctccaaga cagcaaccgc ttcttcacact gctggAACCG	540
ctggggccgt gtgggagagg tcggccatgc aaagatcaac cacttcacaa ggctagaaga	600
tgcaaagaag gactttgaga agaaatttc ggaaaagacc aagaacaact gggcagagcg	660
ggaccacttt gtgtctcacc cggcaagta cacacttac gaagtacagg cagaggatga	720
ggcccaggaa gctgttgta aggtggacag aggcccagtg aggactgtga ctaaggccgt	780
gcagccctgc tccctggacc cagccacgca gaagctcatc actaacatct tcagcaagga	840
gatgttcaag aacaccatgg ccctcatgg cctggatgtg aagaagatgc ccctggaaa	900
gctgagcaag caacagattt cacggggttt cgaggcctt gaggcgctgg aggaggccct	960
gaaaggcccc acggatggtg gccaaagct ggaggagctg tcctcacact tttacaccgt	1020
catcccgcac aacttcggcc acagccgacc cccgccccatc aattccccctg agcttctgca	1080
ggccaagaag gacatgtgc tgggtgtgg ggacatcgag ctggcccaagg ccctgcaggc	1140
agtctctgag caggagaaga cggtggagga ggtgccacac cccctggacc gagactacca	1200
gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca aggtgataca	1260
gacctactta gaacagactg gcagcaacca caggtgcctt acacttcaac acatctggaa	1320
agtaaaccaa gaaggggagg aagacagatt ccaggcccac tccaaactgg gtaatcgaa	1380
gctgctgtgg catggcacca acatggccgt ggtggccggcc atcctcaacta gtgggctccg	1440
catcatgcca cattctggtg ggctgtttgg caagggcatc tactttgcct cagagaacag	1500
caagtcaagt ggtatatgtta ttggcatgaa gtgtggggcc caccatgtcg gctacatgtt	1560
cctgggttag gtggccctgg gcagagacca ccataatcaac acggacaacc ccagctgaa	1620
gagcccacct cctggcttcg acagtgtcat tgcccgaggc cacaccgagc ctgatccgac	1680
ccaggacact gagttggagc tggatggcca gcaagtggtg gtggcccaagg gccagccgt	1740
gccctgcccc gagttcagca gctccacatt ctcccagagc gagtacctca tctaccagga	1800
gagcccaactgtt cgcctgcgtt acctgctgaa ggtccacccctc tgagtgcgg ccctgtcccc	1860
cggggtcctg caaggctgga ctgtgatctt caatcatctt gcccacatctt ggtaccctta	1920
tatcacttct tttttcaag aatacaatac gttgttgta actatagtc ccatgtgtta	1980

US 8,859,562 B2

23**24**

-continued

caagatccct	gaacttatgc	ctcctaactg	aaattttgta	ttctttgaca	catctgccca	2040
gtccctctcc	tcccagccca	tggttaccaag	catttgcac	tttacttgc	taagggcagc	2100
ttttataggt	tccacatgt	agttagatca	tgcagtgtt	gtctttctgt	gcctggctta	2160
tttcactcag	cataatgtgc	accgggttca	cccatgtttt	cataaatgac	aagattcct	2220
ccttaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa		2263

<210> SEQ ID NO 7

<211> LENGTH: 4491

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

cgaagatggc	gggtcgcggt	cgtctcaggc	atcatcacca	ccatcatcaa	caacagctcc	60
agccccgcccc	aggggcttca	gcccggccgc	cgcacactcc	tcccccaactc	agccctggcc	120
tggccccggg	gaccacccca	gcctctccca	cggccagcgg	cctggccccc	ttcgcctccc	180
cgcggcacgg	cctagcgctg	ccggagggggg	atggcagtcg	ggatccgccc	gacaggcccc	240
gatccccggg	cccggttgc	gttaccagct	gttgcagtc	caccagcaca	atctgtaccg	300
tcgcggccgc	tcccggtgtc	ccagcggtt	ctacttcate	tgcgcgtggg	gtcgctccca	360
acccagccgg	cagtggcagt	aacaattc	cgtcgcttc	ttcttccccc	acttcttcct	420
catttcttc	tccatctcc	cctggatcga	gttggcgga	gagccccgag	gcggccggag	480
ttagcagcac	agcaccactg	gggcctgggg	cagcaggacc	tgggacagg	gtcccgacag	540
tgagcggggc	cctacgggaa	ctgctggagg	cctgtcgcaa	tggggacgtg	tcccggttaa	600
agaggcttgt	ggacgcggca	aacgtaaatg	caaaggacat	ggccggccgg	aagtcttctc	660
ccctgcactt	cgtgcaggt	tttggaaagga	aggatgttgt	agaacactta	ctacagatgg	720
gtgctaatgt	ccacgcttgt	gatgatggag	gtctcatccc	gttcataat	gcctgttctt	780
ttggccatgc	tgaggttgt	agtctgttat	tgtgccaagg	agctgatcca	aatgccagg	840
ataactggaa	ctatacacct	ctgcatgaag	ctgcttattaa	agggaaagatc	gatgtgtgca	900
ttgtgctgt	gcagcacgga	gtgtacccaa	acattcggaa	cactgtatgg	aaatcagccc	960
tggacactggc	agatcctca	gcaaaagctg	tccttacagg	tgaatacaag	aaagacgaac	1020
tcctagaagc	tgcttaggat	ggtaatgaag	aaaaactaat	ggcttactg	actcctctaa	1080
atgtgaattg	ccatgcaagt	gatggggcga	agtcgactcc	tttacatcta	gcagcgggct	1140
acaacagagt	tcgaatagtt	cagcttctc	ttcagcatgg	tgctgtatgtt	catgaaaaag	1200
acaaagggtgg	acttgtgcct	cttcataatg	catgttcat	tggacattat	gaagtccacag	1260
aactgctact	aaagcatgga	gcttgttta	atgcatgga	tctctggcag	tttactccac	1320
tgcacgaggc	tgcttccaag	aaccgtgtag	aagtctgtc	tttggttactt	agccatggcg	1380
ctgatcctac	gttagtcaac	tgccatggca	aaagtgttgt	ggatatggct	ccaaactccgg	1440
agcttaggga	gagattgact	tatgaattt	aaggcatcc	tttactacaa	gcagccagag	1500
aagcagactt	agctaaagtt	aaaaaaacac	tgcgtctgga	aatcattaat	ttcaaaacaac	1560
cgcagtctca	tgaaacagca	ctgcactgt	ctgtggcc	tctgcataccc	aaacgtaaac	1620
aagtgcacaga	attgttactt	agaaaaggag	caaatgttaa	tgaaaaaaat	aaagatttca	1680
tgactccct	gcatgttgca	gcccggaaagag	cccataatga	tgtcatggaa	gttctgcata	1740
agcatggcgc	caagatgaat	gcactggaca	cccttggtca	gactgttttgc	catagagccg	1800

US 8,859,562 B2

25**26**

-continued

cccttagcagg ccacacctgca	acctggccgc	tcctgcttag	ttacggctct	gaccctcca	1860
tcatctccctt acaaggcttc	acagcagcac	agatggcaa	tgaagcagt	cagcagattc	1920
tgagtgtgag ttacggctct	gaccctcca	tcatctccctt	acaaggcttc	acagcagcac	1980
agatggcaa tgaagcagt	cagcagattc	ttagtgtca	ttcgtagata	gtgatcattc	2040
tacttcagcc ttaatggta	tcttgagacg	ggaagattt	gaaggaaatc	tatccagcat	2100
gtcttcactg tcaacatgaa	gagtacacct	atacgtactt	ctgatgtga	ttatcgactc	2160
ttagaggcat ctaaagctgg	agacttggaa	actgtgaagc	aactttcag	ctctaaaat	2220
gtgaattgtta gagacttaga	gggcggcat	tccacgecct	tacacttcgc	agcaggctac	2280
aacagagtagc acctatacgt	acttctgatg	ttgattatcg	actcttagag	gcatctaaag	2340
ctggagactt ggaaactgtg	aagcaacttt	gcagctctca	aatatgtaat	tgttagagact	2400
tagagggccg gcattccacg	cccttacact	tcgcagcagg	ctacaaccgc	gtgtctgtt	2460
tagagtacct gctacaccac	ggtgccgatg	tccatgccaa	agacaagggt	ggcttggtgc	2520
cccttcataa tgccgttca	tatggacact	atgagggtgc	tgagctttt	gtaaggcatg	2580
gggcttctgt caatgtggcg	gacttatgg	aatttacccc	tctccatgaa	gcagcagcta	2640
aaggaaagta tgaatctgc	aagctcctt	taaaacatgg	agcagatcca	actaaaaaga	2700
acagagatgg aaatacacct	ttggatttg	taaaggaagg	agacacagat	attcaggact	2760
tactgaaagg ggtatgctgt	ttgttggatg	ctgccaagaa	gggctgcctg	gcaagagtgc	2820
agaagctctg taccccaagag	aatatcaact	gcagagacac	ccagggcaga	aattcaaccc	2880
ctctgcaccc ggcagcaggc	tataataacc	tggaagttag	tgaatatctt	ctagagcatg	2940
gagctgatgt taatgcccag	gacaagggtg	gtttaattcc	tcttcataat	gcggcatctt	3000
atgggcatgt tgacatagcg	gttttattga	taaaataccaa	cacgtgtta	aatgcaacag	3060
ataagtgggc gtttactccc	ctccatgaag	cagccagaa	aggaaggacg	cagctgtgc	3120
cccttcctct agcgcacatgt	gcagacccca	ccatgaagaa	ccaggaaggc	cagacgcctc	3180
tggatctggc aacagctgac	gatatcagag	ctttgctgat	agatgccatg	cccccagagg	3240
ccttacctac ctgttttaaa	cctcaggctt	ctgttagt	tgcctctctg	atctcaccag	3300
catccacccc ctctgcctc	tcggctgcca	gcagcataga	caacctca	ggccctttag	3360
cagagttggc cgtaggagga	gcctccaatg	cagggatgg	cgccgcggga	acagaaagga	3420
aggaaggaga agttgctggt	cttgacatga	atatcagcca	atttctaaaa	agccttggcc	3480
ttgaacaccc tcgggatatc	tttgaaacag	aacagattac	actagatgt	ttggctgata	3540
tgggtcatga agagttgaaa	gaaataggca	tcaatgcata	tgggcacccgc	cacaattaa	3600
tcaaaggagt agaaagactc	ttaggtggac	aacaaggcac	caatccttat	ttgactttc	3660
actgtgttaa tcagggaaacg	atttgctgg	atcttgc	agaagataaa	gaatatcagt	3720
cagtggaaaga agagatgca	agtactattc	gagaacacag	agatgggtgt	aatgctggcg	3780
gcatttc当地 cagatacaat	gtcattcgaa	ttcaaaaat	tgtcaacaag	aagttaggg	3840
agcggttctg ccaccgcac	aaggaagtgt	ctgaggagaa	tcacaaccat	cacaatgagc	3900
gcattgtgtt tcatgggttct	ccttcatta	atgcccattat	tcataaagg	tttgcgtgac	3960
gacatgcata cataggagga	atgtttgggg	ccgggat	tttgctgaa	aactcctcaa	4020
aaagcaacca atatgtttat	ggaatttggag	gagaaacagg	ctgcctaca	cacaaggaca	4080
ggtcatgcta tatatgtcac	agacaaatgc	tcttctgt	agtgaccctt	gggaaatcct	4140
ttctgcagtt tagcaccatg	aaaatggccc	acgcgcctcc	agggcaccac	tcagtcattg	4200

US 8,859,562 B2

27**28**

-continued

gtagaccgag	cgtcaatggg	ctggcatatg	ctgaatatgt	catctacaga	ggagaacagg	4260
catacccaga	cataccccc	acttaccaga	tcatgaagcc	agaagcccc	tcccgaccg	4320
caacagccgc	agagcagaag	acctagtgaa	tgcctgctgg	tgaaggccag	atcagattc	4380
aacctgggac	tggattacag	aggattgtt	ctaataacaa	catcaatatt	ctagaagtcc	4440
ctgacagcct	agaaaataaagc	tgttgtctt	ctataaaagca	ttgctatagt	g	4491

<210> SEQ ID NO 8

<211> LENGTH: 6189

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

cgcggccct	cgttagccga	aacctggcca	gcccgtgcc	ggccactgcg	cacgcccggg	60
acgacgtcac	gtgcgcctcc	ggggctggac	ggagctggca	ggagggccct	tgccagcttc	120
cgcggccggc	tcgtttcagg	acccggacgg	cggattcgcg	ctgcctccgc	cgccgggggg	180
cagccggggg	gcagggagcc	cagcgagggg	cgcgcgtggg	cgcggccatg	ggactgcgcc	240
ggatccgggt	acagcaggga	gccaagcggc	cggggccctg	agcgcgttct	ctccgggggg	300
cctcgccctc	ctgttcgggg	ggccgggggt	cctgttcggg	ttgtctggcgc	tgttgtggc	360
tgtgggggg	gccaggatca	tgtcggtc	cgcgtgcgc	ggccggggag	cggcctgcgc	420
gagcgccggc	gcegagggccg	tggagccggc	cgcggagag	ctgttcgagg	cgtgcgcgaa	480
cggggacgtg	gaacgagtca	agaggctgg	gacgcctgag	aaggtaaca	gccgegacac	540
ggcgggcagg	aaatccaccc	cgtgcactt	cgcgcaggt	tttggccgga	aagaegtgt	600
tgaatatttgc	cttcagaatgt	gtgcacatgt	ccaagcacgt	gatgtatggg	gccttattcc	660
tcttcataat	gcatgtctt	ttggtcatgc	tgaagtatgc	aatctccctt	tgcgacatgg	720
tgcagacccc	aatgctcgag	ataattggaa	ttatactcct	ctccatgaag	ctgcaattaa	780
aggaaaagatt	gatgtttgca	ttgtgttgt	acagcatgga	gctgagccaa	ccatcgaaaa	840
tacagatgga	aggacagcat	tggatattgc	agatccatct	gccaaagcag	tgcttactgg	900
tgaatataag	aaagatgaac	tcttagaaag	tgccaggagt	ggcaatgaag	aaaaaatgtat	960
ggctctactc	acaccattaa	atgtcaactg	ccacgcgaat	gatggcagaa	agtcaactcc	1020
attacatttg	gcagcaggat	ataacagagt	aaagattgta	cagctgttac	tgcaacatgg	1080
agctgtatgtc	catgctaaag	ataaaagggtga	tctgttatcca	ttacacaatg	cctgttctta	1140
tggtcattat	gaagtaactg	aacttttgtt	caagcatggt	gcctgtttaa	atgcaatgg	1200
cttggccaa	ttcactcctc	ttcatgaggc	agcttctaaag	aacagggtt	aagtatgttc	1260
tcttccttta	agtatgttg	cagacccaaac	actgctcaat	tgtcacaata	aaagtgttat	1320
agacttggct	cccacaccac	agttaaaaga	aagattagca	tatgaattt	aaggccactc	1380
gttgcgtcaa	gctgcacgag	aagctgtatgt	tactcgaatc	aaaaaacatc	tctctcttgg	1440
aatgggtgaat	ttcaagcatc	ctcaaacaca	tgaaacagca	ttgcattgtg	ctgctgcattc	1500
tccatatccc	aaaagaaaagc	aaatatgtga	actgttgctt	agaaaaggag	caaacatcaa	1560
tgaaaagact	aaagaatttct	tgactcctct	gcacgtggca	tctgagaaag	ctcataatga	1620
tgttgttggaa	gtagtggta	aacatgaagc	aaaggtaat	gctctggata	atcttggtca	1680
gacttctctta	cacagagctg	catattgtgg	tcatctacaa	acctggccgc	tactcttgcag	1740
ctatgggtgt	gatcctaaca	ttatatccct	tcagggctt	actgcttac	agatggaaaa	1800

US 8,859,562 B2

29

30

-continued

US 8,859,562 B2

31**32**

-continued

acagaactaa	tttactaat	acaatactgt	gttctttaaa	acacagcatt	tacactgaat	4260
acaatttcat	ttgtaaaaact	gtaaataaga	gcttttgac	tagcccgta	tttatttaca	4320
ttgctttgta	atataaatct	gttttagaac	tgcagcggtt	tacaaaattt	tttcataatgt	4380
attgttcatc	tatacttcat	cttacatcg	catgattgag	tgatctttac	atttgattcc	4440
agaggctatg	ttcagttgtt	agttggaaa	gattgagta	tcagattaa	tttgcgcgt	4500
ggagccctta	tctgtcatta	gaaatcttc	tcatttaaga	acttatgaat	atgtgaaga	4560
ttaatttgt	gataccttg	tatgtatgag	acacattcca	aagagctcta	actatgatag	4620
gtcctgatta	ctaaagaagc	ttctttactg	gcctcaattt	ctagcttca	tgttggaaaa	4680
tttctgcag	tccttctgtg	aaaatttagag	caaagtgc	ctgttttta	gagaaactaa	4740
atcttgctgt	tgaacaatta	ttgtgttctt	ttcatggAAC	ataagtagga	tgttaacatt	4800
tccagggtgg	gaagggtaat	cctaaatcat	ttcccaatct	attctaatta	ccttaaatct	4860
aaaggggaaa	aaaaaaatca	caaacaggac	tgggtagtt	tttacccaa	gtatatttt	4920
tcctgttctt	tttacttggt	tttattgtotg	tatTTatAGC	caatctatac	atcatggta	4980
aacttaaccc	agaactataa	aatgttagtt	tttcagtccc	cttcaggcct	cctgaatggg	5040
caagtgcagt	gaaacagggt	cttcctgtc	ctgggttttc	tctccatgt	gttatgccca	5100
attggaaata	tgcgtcagt	ttgtgcacca	tatggtgacc	acgcctgtgc	tcagttggc	5160
agctatagaa	gaaatgtcg	tcccataaaa	tgccatccct	atttctaata	taacactt	5220
ttccaggaag	catgcttaag	catctgtt	cagagacata	catccattat	ggcttgcaa	5280
tctctttat	ttgttgactc	tagctccct	caaagtgc	gaaagatctt	tactcactt	5340
atgaggacat	tccccatcac	tgtctgtacc	agttcacctt	tatTTacgt	tttattcagt	5400
ctgtaaatta	actggccctt	tgcagtaact	tgtacataaa	gtgctagaaa	atcatgtcc	5460
ttgtcctgag	taagagttaa	tcaagatgg	tgcattctg	gagttgtt	tgtgatgtaa	5520
attatgatca	tatTTaaga	agtcaaATCC	tgtatctgaa	gtgcttttta	tacagctctc	5580
taataattac	aaatatccga	aagtccattt	ttggAACACA	agtggagtagt	gccaatttt	5640
atatgaattt	ttagattat	ctaagcttcc	aggTTTATA	attagaagat	aatgagagaa	5700
ttaatgggt	ttatatttac	attatctctc	aactatgtag	cccattttac	tcacccatgt	5760
agtgaatctg	gaattgttt	tcatgtaaa	tcattgtgg	ctatgagttt	acaatactgc	5820
aaactgtgtt	atTTtatcta	aaccattgt	taatgagtgt	gtttttccat	gaatgaat	5880
accgtgggtc	atatgttagc	atggcagcat	tttcagatag	ctttttgtt	gttggaaagt	5940
tggggTTTG	gggggagggg	gagtttagt	acgttgc	aatagccta	ctttataatg	6000
atgggaatgc	tttttctttt	gttttggat	ttttttttt	gaagtggaaat	ttaactttt	6060
gtgccagtag	tactattata	cccatcttca	gtgtcttact	tgtactgtat	caaattccat	6120
accctcattt	aattcttaat	aaaactgttc	acttgtaaaa	aaaaaaaaaa	aaaaaaaaaa	6180
aaaaaaaaaa						6189

<210> SEQ ID NO 9

<211> LENGTH: 5490

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

cgcccgccca gccccggggg cagggaaagc ctaaattacg gaattaccgc gagcaaggag 60

US 8,859,562 B2

33

34

-continued

cgccggatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tcatgggaat
ctttgcataat tggatcttct gtttggaaagt gaagtactta ctcacgcaga agaagaaaa
gctacaaact gacattaagg aaaatggcg aaagtttcc ttttcgttta atcctcgtg
cacacatata atcttagata atgctgtatgt tctgagtcag taccaactga attctatcca
aaagaaccac gttcatatgg caaacccaga ttttatatgg aatctatca gagaaaagag
actcttgat gtaaagaatt atgatcctta taagccccgt gacatcacac cacccctgt
tcagaaggcg agcagttctg aagtgaaaac agaaggctta tgcccgacat gtccacaga
ggaggaagac actgttggAAC tcactgagtt tggatcgac aatgttggaa ttccatct
tcctcaagat tttgaagttg caaaaatataa caccttggag aaagtggaa tggagggagg
ccaggaagct gtgggttgtt agcttcgttgc ttcgcggacat tccaggact gtccttcct
gatatcctca cacttcctcc tggatgttgc catggagact agaaggacat ttgttataaa
gaaaacctct gaagatgcaa gtgataactt tggaaattac attgaagaac tgaagaaaca
aggatttctca ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt
gcaagcatgg cttttggagg aagtcatgaa ttcaagcaactt ctgagccaaag aggtgagcga
tttagtagag atgatttggg cagaggccctt gggccacctg gaacacatgc ttctcaagcc
agtgaacagg attagcctca acgtgttgc caaggcagag gggatttcc ttcttagttaaa
ggcagcactg aaaaatggag aaacagcaga gcaattgca aagatgtga cagagttta
cagactgata cctcacaag gcacaatgcc caaagaagtg aacctggac tattggctaa
gaaagcagac ctctgcccacg taataagaga catggtaat gtctgtggaa ctaatttgc
caaaacccaaac ccaccatccc tggccaaata ccgagctttt aggtgaaaa ttgagcatgt
tgaacagaat actgaagaat ttctcagggt tagaaaagag gtttgcaga atcatcacag
taagagccca gtggatgttgc tgcagatatt tagagttggc agagtgaatg aaaccacaga
gtttttgagc aaacttggta atgtgaggcc cttgttgcatt ggttcttcctg tacaacat
cggtggaaatc ttgtgtcgag gtttgcattt acccaaagta gtggaaatgc gtgtgtgc
aagaacagac gtcggaaacc ttggaaatgg gatttatttc agtgatttgc tcagtacaag
tatcaagtac tcacaccccg gagagacaga tggcaccaga ctccctgtca tttgtgacgt
agccctcgaa aagtgtatgg acttacatga gaaggactt cccttaactg aagcaccacc
aggctacgac agtgtgtcatg gagtttccaa aacagccctt gtcaccacag actttggaga
tgatgaattt gtttgcattttaa aaccaatca ggttaaaatgg aatataattttaaatttcc
catgcctgaa gatcgataa aggacttca tccttagtgc catactgaat tagaggaata
cagacctgag ttttcaaaattt tttcaaaaggt tgaagattac cagttaccag atgcacaaac
ttccagcaggcc accaaggccg gcctccaggaa tgcctctggg aactttggcc ctctggagga
tgtccacatc aaagggagaa tcatagacac tgtagcccg gtcattttt ttcagacata
cacaataaaa agtcacgtgc ccattgaggc aaaatataatc ttcccttgg atgacaaggc
cgctgtgtt ggttccgaag ctttcatca tggaaatggc atagttggag agattaaaga
gaaggaagaa gcccgacaaag agtacccatg agccgtgacc cagggccatg gcgcttaccc
gtatgttgc gatgttgcgg acgttttac tggatgttgc gggaaacttac cccctaaaggc
taaggttctt ataaaaatattt cctacatcac agaactcgc atcctggca ctgttgggt
cttttcatg cccggccacccg tagcaccctg gcaacaggac aaggcttga atgaaaaccc
tcaggatatac gtagagaaatggg tttgtataaa agaaatggg acaaaatggg gcttctt
24000

US 8,859,562 B2

35

36

-continued

US 8,859,562 B2

37**38**

-continued

acactggcag gatgctgtgc ctggacaga actcctcagt ctacagacag aggatggctt	4860
ctggaaacctt acaccagaac tgggacttat attaaatctt aatacaaatg gtttgacag	4920
ctttcttaaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcttgg	4980
cctaattgcc acaatgctgg tactacagt tattcgcacc aggttgaaaa aagaggaaat	5040
agtgttcaaa tcactgtatga aaatggatga cccttctatt tccaggata ttccctgggc	5100
ttttgaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc	5160
tatctgccc cggcttgaac tggggAACGA ctgggactct gccaccaagc agttgtgg	5220
actccagccc ataaggactg tgtccccctct tcatacgatgc ctccattaca gtcaaggcta	5280
agtcaaatga aactgaattt taaactttt gcatgcttct atgtagaaaa taatcaaatg	5340
ataatagata attataatga aacttcattt aggtttcatt cagtgttagca attactgtct	5400
ttaaaaatta agtggaaagaa gaattactttt aatcaactaa caagcaataa taaaatgaaa	5460
cttaaaataa aaaaaaaaaa aaaaaaaaaa	5490

The invention claimed is:

- 25
1. A method of treatment of cancer cells defective in homologous recombination (HR), the method comprising: identifying a human patient with a familial predisposition to gene-linked hereditary cancer,

wherein said cancer comprises cancer cells defective in homologous recombination; identifying a compound which inhibits PARP-1, and administering to said human patient a therapeutically effective amount of said compound.

* * * * *